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ABSTRACT: In this study, we report the design and synthesis of a
series of novel thiophene-arylamide compounds derived from the
noncovalent decaprenylphosphoryl-β-D-ribose 2′-epimerase
(DprE1) inhibitor TCA1 through a structure-based scaffold
hopping strategy. Systematic optimization of the two side chains
flanking the thiophene core led to new lead compounds bearing a
thiophene-arylamide scaffold with potent antimycobacterial activity
and low cytotoxicity. Compounds 23j, 24f, 25a, and 25b exhibited
potent in vitro activity against both drug-susceptible (minimum
inhibitory concentration (MIC) = 0.02−0.12 μg/mL) and drug-
resistant (MIC = 0.031−0.24 μg/mL) tuberculosis strains while
retaining potent DprE1 inhibition (half maximal inhibitory concentration (IC50) = 0.2−0.9 μg/mL) and good intracellular
antimycobacterial activity. In addition, these compounds showed good hepatocyte stability and low inhibition of the human ether-a-̀
go-go related gene (hERG) channel. The representative compound 25a with acceptable pharmacokinetic property demonstrated
significant bactericidal activity in an acute mouse model of tuberculosis. Moreover, the molecular docking study of template
compound 23j provides new insight into the discovery of novel antitubercular agents targeting DprE1.
■ INTRODUCTION
Tuberculosis (TB) is a chronic infectious disease caused
primarily by pathogen Mycobacterium tuberculosis (M. tuber-
culosis). TB is one of the top 10 causes of death and the leading
cause of mortality stemming from a single infectious agent. In
2020, the World Health Organization (WHO) reported that
approximately 1.2 million human immunodeficiency virus
(HIV)-negative people had died and 10 million new TB cases
were identified. Globally, the TB incidence rate is falling but not
fast enough to reach the 2020 milestone of a 20% reduction
between 2015 and 2020.1 The COVID-19 pandemic threatens
to reverse the recent progress in reducing the global burden of
TB disease. The requirement for prolonged treatment with first-
line drugs coupled with often difficult-to-manage side effects
routinely leads to poor patient compliance and results in the
accelerated emergence of drug-resistant strains of M. tuber-
culosis. Research focusing on the development of novel small
molecules with activity against multidrug-resistant tuberculosis
(MDR-TB) and extensively drug-resistant tuberculosis (XDR-
TB) remains a significant challenge.2,3
The cell wall biosynthetic pathways have been identified as
promising targets for the development of antitubercular
agents.4,5 Decaprenylphosphoryl-β-D-ribose 2′-epimerase
(DprE1) is crucial for mycobacterial cell wall biosynthesis.6
DprE1 catalyzes the flavin adenine dinucleotide (FAD)-
dependent oxidation of decaprenylphosphoryl-β-D-ribose
(DPR) to decaprenylphosphoryl-2′-keto-D-erythro-pentofura-
nose (DPX). DPX is then reduced by decaprenylphosphoryl-D-
2-ketoerythropentose reductase (DprE2) to generate decap-
renylphosphoryl-β-D-arabinofuranose (DPA), which is a unique
precursor for the synthesis of cell-wall arabinans.7,8 Further-
more, DprE1 is specific to mycobacteria and actinomycetes,
providing inherent biochemical selectivity over human cells and
other bacterial species.9 Therefore, DprE1 has become a
vulnerable target for treatment of drug-sensitive TB as well as
MDR/XDR-TB.10
A number of small molecules as anti-TB agents have so far
been reported, with the benzothiazinones (BTZs) being the
most well-developed and studied DprE1 inhibitors.11,12 Two
compounds, BTZ043 and its next-generation analogue
PBTZ169 (Macozinone), display potent antimycobacterial
activity (minimum inhibitory concentrations (MICs) <0.016
μg/mL), and they are currently undergoing clinical develop-
ment.13,14 These two small molecules likely impart their
biological activity through formation of a covalent bond with
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Cys387 in the active site of DprE1. Recently, several structurally
diverse noncovalent inhibitors of DprE1 have been described in
the literature, most notably TBA-7371 and TCA1 (Figure
1).6,15−19 These compounds have the additional bonus of
avoiding the nitro group used in BTZs, a well-established
structural alert, and show the potential for further development.
1,4-Azaindole TBA-7371 has entered clinical development, and
the structure−activity relationship (SAR) of this series has been
fully explored and is well understood.20,21 TCA1 was identified
via a cell-based phenotypic screen for inhibitors of biofilm
formation in mycobacteria, which has bactericidal activity
against replicating and nonreplicating M. tuberculosis.22,23
Inspired by the distinct thiophenamide moiety of TCA1, we
have focused on the identification of a novel series of thiophene-
arylamide compounds with improved activity and druggability
derived from lead compound TCA1 through a scaffold hopping
strategy.
We began by analyzing the binding events displayed in TCA1
with the DprE1 cocrystal structure (Protein Data Bank (PDB):
4KW5) shown in Figure 2a.22 The thiophene moiety of TCA1
binds deeply within the bottom of the active site in DprE1 and
shows that the noncovalent binding events between TCA1 and
DprE1 are dominated by hydrophobic and van der Waals
interactions. Further to these hydrophobic interactions, a clear
hydrogen bond is formed between the thiophene moiety and
His132 coupled with multiple hydrogen-bonding interactions
between the carbonyl groups of TCA1 and residues Lys418 and
Ser228 (Figure 2a). The binding mode indicated that the 2,3-
disubstituted thiophene moiety plays an important role in
maintaining key interactions of the cocrystal structure. The
benzothiazole moiety is oriented parallel to the FAD
isoalloxazine ring and forms additional hydrophobic interactions
to keep critical pharmacodynamic conformation. We speculate
that the addition of a hydrogen-bonding acceptor (HBA) in this
region may enhance binding affinity with DprE1. Moreover, the
terminal carbamate moiety at the 3-position on thiophene is
considered to be metabolically labile and modification to this
region may have an advantageous effect on overall metabolic
stability.
Herein, we designed and synthesized a series of novel
thiophene-arylamide derivatives to explore their structure−
activity relationships (SARs) guided by the aforementioned
crystal structure. These structural modifications were concen-
trated on the arylamide motif and carbamate moiety of TCA1
based on an evaluation of their antimycobacterial activities as
well as preliminary druggability scoring (Figure 2b). A
representative DprE1 inhibitor 25a with acceptable pharmaco-
kinetic (PK) properties demonstrated significant bactericidal
activity in an acute mouse model of tuberculosis. Furthermore,
molecular docking studies of the template compound 23j with
the benzamide moiety provide new insight into the discovery of
novel anti-TB agents targeting DprE1.
■ RESULTS AND DISCUSSION
Molecular Docking Study of Template Compound 23j
in DprE1. We began our study with molecular modeling to
Figure 1. Structures of representative covalent and noncovalent DprE1 inhibitors.
Figure 2. Optimization of TCA1 based on analysis of the cocrystal structure. (a) Noncovalent interactions of TCA1 with DprE1 and modification
regions. (b) Design and optimization of thiophene-arylamide compounds as DprE1 inhibitors.
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understand the binding mode of the template compound 23j in
the active site of DprE1 (Figure 3; PDB: 4KW5). The highest
docking score conformation derived from the CDOCKER
protocol was selected as the best binding pose. The overlay of
the 23j model with the crystal structure of TCA1 in complex
with DprE1 showed similar interactions in the active site (Figure
3a). Hydrogen-bonding interactions were found between
compound 23j and residues Ser228, Lys418, and His132,
which were consistent with the binding mode of TCA1.
Furthermore, the phenyl ring was oriented roughly parallel to
the isoalloxazine of FAD and formed hydrophobic interactions
with residues Gln334 and Cys387. Interestingly, the acyl of
benzamide formed a key hydrogen bond with Tyr60, and the
terminal piperidine interacted with residues Leu317, Arg325,
and Asn324 (Figure 3b). This additional reinforced interaction
of acyl piperidine may enhance the binding affinity and therefore
improve the antimycobacterial activity. This predicted model,
which was in line with our design strategy, prompted us to more
closely explore the SAR exhibited by the thiophene compounds
containing this arylamide moiety.
Chemistry. The synthesis of aryl carboxylic acids with
various amide motifs 4a−p and 7a−l is outlined in Schemes 1
and 2. The substituted aminothiophene intermediates 11a−d,
16a, 16b, 19, and 22a−h were synthesized following the
procedures summarized in Schemes 3−5. The general synthetic
procedures of target compounds 23a−p, 24a−l, and 25a−q
through condensation reactions are illustrated in Schemes 6 and
7.
As shown in Scheme 1, intermediates 3a−p were obtained via
amidation of commercially available methyl 4-(chlorocarbonyl)-
Figure 3.Molecular docking studies of compound 23j in DprE1. (a) Overlay of the 23j (yellow colored) model with the crystal structure of TCA1
(cyan) in complex with DprE1. (b) Docking model of 23j in the binding site of M. tuberculosis DprE1 (PDB: 4KW5).
Scheme 1. Synthesis of Benzoic Acid with Different Amide Substituents 4a−pa
aReagents and conditions: (a) Et3N, CH2Cl2, room temperature (rt), 3 h; (b) 1 mol/L LiOH aqueous solution, CH3OH, rt, 3 h.
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benzoate (1) with the corresponding amines 2a−p in the
presence of triethylamine. The obtained 3a−p were converted
to intermediates 4a−p via hydrolysis with aqueous lithium
hydroxide solution.
Scheme 2. Synthesis of Aryl Carboxylic Acid with Piperidinamide Substituents 7a−la
aReagents and conditions: (a) piperidine, 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), Et3N,
dimethylformamide (DMF), rt, 10 h; (b) 1 mol/L LiOH aqueous solution, CH3OH, rt, 3 h.
Scheme 3. Synthesis of Aminothiophene with Different Amide Substituents 11a−da
aReagents and conditions: (a) di-tert-butyl decarbonate ((Boc)2O), 4-dimethylaminopyridine (DMAP), Et3N, CH2Cl2, rt, 6 h; (b) 1 mol/L NaOH
aqueous solution, CH3OH, reflux, 4 h; (c) alicyclic amines, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), 1-
hydroxybenzotriazole (HOBt), Et3N, DMF, rt, 12 h; (d) trifluoroacetic acid (TFA), CH2Cl2, rt, 2.5 h.
Scheme 4. Synthesis of Aminothiophene Intermediates 16a, 16b, and 19a
aReagents and conditions: (a) phosphorus oxychloride, DMF, toluene, 80 °C, 3 h; (b) 2,5-dihydroxy-1,4-dithiane, Et3N, CH3OH, 50 °C, 2.5 h; (c)
oxalyl chloride, 1,2-dichloroethane, reflux, 4 h; (d) ethylamine, CH3CN, −10 °C, 3 h.
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According to Scheme 2, the condensation reactions of various
aryl carboxylic acids 5a−l with piperidine afforded correspond-
ing intermediates 6a−l in the presence of 2-(7-aza-1H-
benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluoro-
phosphate (HATU). The hydrolysis of 6a−l led to key
intermediates 7a−l.
As shown in Scheme 3, methyl 2-aminothiophene-3-
carboxylate (8) was reacted with (Boc)2O to form intermediate
9, and subsequent hydrolysis led to thiophene carboxylic acid
10. Key intermediates 11a and 11b were obtained via
condensation of 10 with alicyclic amines and routine N-Boc
deprotection. In addition, intermediates 11c and 11d were
prepared from 8 via a two-step hydrolysis/condensation strategy
without the need for N-Boc protection and deprotection.
The synthesis of aminothiophene intermediates 16a, 16b, 19,
and 22a−h is summarized in Schemes 4 and 5. 2-Cyanoacetic
acid (13) was treated with carbamates 14a, 14b in the presence
of phosphorus oxychloride to form intermediates 15a and 15b.
Aminothiophene intermediates 16a and 16b were obtained by
heterocyclization of 15a, 15b with 2,5-dihydroxy-1,4-dithiane
via a Gewald reaction.23 2-Cyanoacetamide (17) was reacted
with oxalyl chloride under reflux to provide the isocyanate, and a
subsequent reaction with ethylamine gave intermediate 18
without further purification, which followed theGewald reaction
to afford aminothiophene intermediate 19. The condensation
reactions of 2-cyanoacetic acid (13) with various aryl amines
20a−h delivered the corresponding intermediates 21a−h in the
presence of EDCI with DMAP at room temperature. The
Gewald heterocyclization of 21a−h with 2,5-dihydroxy-1,4-
dithiane produced aminothiophene intermediates 22a−h.
As illustrated in Schemes 6 and 7, target compounds 23a−p,
24a−l, and 25a−q were conveniently obtained through the
condensation reaction with aryl carboxylic acids and amino-
thiophenes. Ethyl(2-aminothiophene-3-carbonyl)carbamate
(16a) was subjected to the condensation reaction with various
4-carbamoylbenzoic acids 4a−p in the presence of HATU to
Scheme 5. Synthesis of Aminothiophene Intermediates 22a−ha
aReagents and conditions: (a) EDCI, DMAP, DMF, rt, 24 h; (b) 2,5-dihydroxy-1,4-dithiane, Et3N, CH3OH, 50 °C, 7 h.
Scheme 6. Synthesis of Target Compounds 23a−p and 24a−la
aReagents and conditions: (a) HATU, Et3N, DMF, rt, 12 h; (b) SOCl2, DMF, CH2Cl2, reflux, 3 h; (c) Et3N, DMAP, tetrahydrofuran (THF), rt, 3
h.
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afford the corresponding products 23a−p. In the same way, the
target products 24a−l were obtained from 16a and the
corresponding carbamoyl aromatic acid or carbamoyl benzoyl
chloride.
4-(Piperidine-1-carbonyl)benzoic acid (4j) was reacted with
16b, 19, 11a−d, and 22a−h to afford the corresponding
products 25a, 25c, 25e−h, 25i−j, and 25l−q under the standard
condensation conditions. The subsequent hydrolysis of 25awith
aqueous lithium hydroxide provided compound 25d. In
addition, 3-fluoro-4-(piperidine-1-carbonyl)benzoic acid (7f)
was condensed with 16b or 22b to form the desired products
25b or 25k, respectively.
SAR Optimization Strategy. The target compounds were
evaluated for their activities against M. tuberculosis H37Rv using
themicroplate Alamar blue assay (MABA).Minimum inhibitory
concentration (MIC) was defined as the lowest concentration
resulting in a reduction in fluorescence of ≥90% relative to the
mean of replicate bacterium-only controls. The compounds with
MIC less than 1 μg/mL were further tested for mammalian cell
cytotoxicity using Vero cells measured by the concentration
required for inhibiting 50% cell growth (half maximal inhibitory
concentration (IC50)) as compared to the no-treatment control.
Tables 1−9 summarize the biological data including in vitro and
in vivo anti-TB activity, toxicity, metabolic stability, PK, and
target validation for these novel thiophene-arylamide deriva-
tives. TCA1, isoniazid (INH), and rifampicin (RFP) were used
as reference compounds for the anti-TB activity assay.
Keeping 2,3-disubstituted thiophene as the key core, initial
MIC-based SAR studies against M. tuberculosis around the lead
compound TCA1 led to the first thiophene-benzamide series.
The analysis of noncovalent interactions of TCA1 with DprE1
and modification sites (Figure 2) indicated that the binding
pocket in this active site is deep and not fully occupied by the
terminal benzothiazole moiety of the 2-position side chain on
the thiophene ring. Therefore, a variety of benzamides with
different physical and chemical properties were introduced to
further improve the antimycobacterial activity and druggability
profile. As listed in Table 1, to our delight, compound 23a with
the terminal propylamine exhibited good potency with
improved MIC compared with TCA1 (0.2 vs 0.48 μg/mL).
Furthermore, compound 23a displayed lower cytotoxicity
against Vero cells with IC50 > 64 μg/mL (SI > 320). Encouraged
by the promising results, we evaluated a series of secondary
amines and the bulky cyclic amines at the terminal of the side
chain. The subsequent results revealed that diethylamine (23c,
MIC = 0.28 μg/mL) was tolerated at the R1 and R2 positions,
whereas the slightly smaller ethyl(methyl) amine (23b, MIC =
0.95 μg/mL) showed a decrease in activity. Encouraged by this
result, large substituents, such as amantadine, cyclohexylamine,
and aniline moieties were introduced to the side chain, aiming to
explore the optimum volume at the R1 and R2 sites. Compounds
23d and 23g bearing amantadine and aniline moieties,
respectively, showed improved antimycobacterial activities as
compared to the reference compound TCA1 (0.12 vs 0.48 μg/
mL) but showed a certain level of cytotoxicity. Additionally,
increasing the overall volume through the addition of gem-
dimethyl to the cyclohexylamine led to lower potency (23e and
23f). Based on the above results, conformationally restricted
secondary amines were embedded at the terminal of the side
chain to further investigate the most favorable size for optimal
occupancy of hydrophobic pockets of DprE1. The results
indicated that smaller substituents such as azetidine (23h, MIC
= 0.84 μg/mL) led to lower potency, while the larger pyrrolidine
(23i, MIC = 0.20 μg/mL), piperidine (23j, MIC = 0.02 μg/mL),
Scheme 7. Synthesis of Target Compounds 25a−qa
aReagents and conditions: (a) HATU, Et3N, DMF, rt, 12 h; (b) 1 mol/L LiOH aqueous solution, CH3OH, reflux, 2 h; (c) EDCI, HOBt, Et3N,
DMF, rt, 24 h.
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and azepane (23k, MIC = 0.22 μg/mL) moieties showed
improved antimycobacterial activities. In particular, compound
23j showed a significant improvement inMIC, corresponding to
a 24-fold enhancement of potency relative to TCA1 (0.02 vs 0.48
μg/mL). In addition, 23j also displayed high selectivity index (SI
> 3200), indicating a good safety profile. Subsequently, the
addition of methyl to the piperidine generated compound 23l,
which showed a MIC of 0.03 μg/mL, demonstrating its
equivalency in antimycobacterial activity to 23j. The replace-
ment of methyl (23l, MIC = 0.03 μg/mL) with methoxyl (23m,
MIC = 0.12 μg/mL) or difluoro (23n, MIC = 0.25 μg/mL)
substituents resulted in lower potency. The bioisosteric
replacement strategy to replace methylene (23j, MIC = 0.02
μg/mL) with an oxygen (23o, MIC = 1.66 μg/mL) or a sulfur
(23p, MIC = 0.33 μg/mL) atom caused a significant decrease in
antimycobacterial activity.
Based on the results from Table 1, coupled with the molecular
docking studies, and keeping the privileged acyl piperidine
fragment, we decided to explore the effect of the aryl moiety on
antimycobacterial activity. Compared to compound 23j,
substitution at the meta-position of the phenyl ring instead of
the para-position led to a marked decrease in potency, as
Table 1. SAR of Thiophene-arylamide Compounds at R1 and
R2 Sites
aMIC against M. tuberculosis H37Rv.
bSI = selectivity index, IC50/
MIC.
Table 2. SAR of Thiophene-arylamide Compounds at the Ar
Site
aMIC against M. tuberculosis H37Rv.
bSI = selectivity index, IC50/
MIC.
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exemplified by compound 24a (MIC = 3.70 μg/mL). We next
explored the introduction of halo, nitro, and methyl substituents
on the phenyl ring, which have the potential to form π−π
interactions in the hydrophobic pocket of DprE1. Introducing
fluoro, chloro, and bromo substituents to the phenyl ring
afforded compounds 24b−d, which displayed good activity with
a range of MICs 0.12−0.49 μg/mL. The involvement of the
strongly electron-withdrawing nitro group (24e, MIC = 1.86
μg/mL) led to lower potency. Compound 24f exhibited a
significant increase in potency by altering the position of the
fluoro group, corresponding to a 10-fold enhancement of
potency relative to 24b (MIC < 0.016 vs 0.12 μg/mL). The
introduction of a methyl group (24g, MIC = 0.12 μg/mL) at the
same position resulted in equal potency compared to 24b.
However, replacement with naphthalene (24h, MIC = 3.13 μg/
mL) and biphenyl (24i, MIC = 7.76 μg/mL) caused an obvious
decrease in activity. Subsequently, introduction of smaller five-
membered aromatic heterocycles, such as thiophene (24j, MIC
= 0.14 μg/mL), furan (24k, MIC = 0.37 μg/mL), and pyrrole
(24l, MIC = 1.77 μg/mL) resulted in moderate to good
antimycobacterial activity. Accordingly, we drew the conclusion
that a phenyl ring bearing the electron-withdrawing fluoro
substituent was the best tolerated at the Ar site.
Since the thorough SAR at the 2-position side chain of
thiophene has been investigated, our attention shifted to the
exploration of the 3-position with substituents at the R3 site. As
listed in Table 3, compounds 25a and 25b with imide methyl
ester showed better antimycobacterial activity than TCA1 (MIC
0.19 and 0.03 μg/mL vs 0.48 μg/mL). Among them, fluoro-
substituted phenyl derivative (25b) showed a MIC of 0.03 μg/
mL and an SI value above 2133. Replacing the ethyl ester (23j)
with ethyl amide (25c) resulted in a dramatic loss of
antimycobacterial activity. Removing the terminal acyl ester
also led to an inactive compound (25d). Next, keeping the
terminal acyl ester moiety, rigid alicyclic amines (25e−h) were
introduced to further evaluate the size differential of substituents
at the R3 site; however, all sterically encumbered substituents
were not tolerated, resulting in a large loss of potency. When we
replaced the carbamate with various rigid aromatic heterocycles
aiming to enhance metabolic stability, compounds with meta-
substituted pyrimidine (25j, 25k, and 25l) showed good
antimycobacterial activity, especially 25l with a MIC of 0.2
μg/mL. The introduction of thiazole, pyridine, and benzothia-
zole led to the total loss of potency (25i, 25n, 25o, and 25q).
In Vitro Anti-XDR-TB Activity and Intracellular Anti-
mycobacterial Activity. Considering that most thiophene-
arylamide derivatives displayed potent activity against M.
tuberculosisH37Rv, some representative compounds were further
tested against two XDR-TB isolated clinical strains (Table 4). It
is gratifying to note that the selected compounds, together with
reference TCA1, demonstrated potent activities against XDR-
TB strains. In particular, compounds 23j, 24f, and 25b displayed
very potent activity against both drug-susceptible and drug-
resistant tuberculosis in vitro, compared to TCA1. Furthermore,
we conducted an additional assay to assess the MIC against
PBTZ169- and bedaquiline-resistant strains ofM. tuberculosis for
the representative compounds. The results revealed that the
thiophene-arylamide derivatives showed no significant cross
resistance to the covalent DprE1 inhibitor PBTZ169 and ATP
synthase inhibitor bedaquiline. The results indicated that these
novel thiophene-arylamide derivatives are noncovalent DprE1
inhibitors and represent promising additions in the combination
regiment for the treatment of drug-resistant TB.
Table 3. SAR of Thiophene-arylamide Compounds at X and
R3 Sites
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Since M. tuberculosis is an intracellular pathogen and survives
in macrophages, we investigated the selected potent compounds
for antimycobacterial activity in an intracellular macrophage
infection model. As shown in Table 5, 0.75−1.34 log10 CFU
reduction in macrophages was observed following treatment
with selected compounds for 3 days at 10 μg/mL. Most notably,
compounds 23j, 24f, and 25l exhibited better intracellular
activity with a reduction of∼1 log10 CFU (compared to TCA1 =
0.61 log10 CFU) and similar to the positive control RFP at 5 μg/
mL, although these compounds did not display the significant
dose−response compared to the reduced colony-forming unit
(CFU) data at 10 μg/mL, which may be related to either the
mechanism of action of the DprE1 inhibitor as a fast bactericidal
or the permeability of the cell wall to the specific compounds.
The above encouraging data drove us to further explore these
promising thiophene-arylamides in preliminary druggability
profiles.
In Vitro ADME/T Assay and In Vivo Pharmacokinetic
Property Evaluation. To identify the metabolic and toxic
liabilities of our thiophene-arylamide scaffold, the selected
compounds, along with the reference TCA1, were evaluated for
their hepatocyte stability, cytotoxicity against mammalian
HepG2 cells, and human ether-a-̀go-go related gene (hERG)
liability. As presented in Table 6, we were pleased to find that all
selected compounds exhibited no cytotoxicity against HepG2
cells with IC50 > 64 μg/mL. In addition, low inhibition profiles of
the hERG channel (IC50 > 20 μM) across the series indicated a
low risk of blocking the cardiac potassium channel and causing
QT prolongation. Although the selected compounds showed
some metabolic liability in mouse hepatocytes compared to
TCA1, they displayed significant superior stability in human
hepatocytes (t1/2 = 20.3−72.5 vs 5.97 min).
Spurred on by the pronounced anti-TB activity and structural
diversity, compounds 24f and 25a were chosen for further
evaluation of their metabolic features in Balb/c mice.
Pharmacokinetic (PK) studies for compounds 24f, 25a, and
TCA1 were performed in Balb/c mice, following a single oral
and an intravenous dose (Table 7). Compound 25a exhibited
high plasma exposure (area under the curve (AUC)0−∞ = 657
ng·h/mL) and highmaximum plasma concentration (Cmax = 486
ng/mL) after oral administration, compared to compound 24f
with AUC0−∞ = 57.9 ng·h/mL and Cmax = 25.4 ng/mL. In
addition, the oral bioavailability of 24f was very low (F = 2.3%)
and clearance was high, which was dropped off in further studies.
Moreover, TCA1 produced a much higher exposure concen-
tration than 25a and possessed a 5-fold enhancement of oral
bioavailability. Based on the results of PK profiles, compound
25a with acceptable oral bioavailability (F = 7.9%) was deemed
worthy of further evaluation in in vivo efficacy studies.
In vivo Efficacy Study on Compound 25a in a Mouse
Model of TB. The in vivo efficacy of compound 25a and TCA1
was conducted in Balb/c mice in an acute TB infection model.
Compound 25a and reference TCA1were orally administered at
100 mg/kg, whereas the positive control, INH, was given at 25
mg/kg. The same formulation, 0.5% carboxymethylcellulose
(CMC) in water, was used for all compounds tested. After three
weeks of treatment, the mice were sacrificed and the number of
colony-forming units (CFUs) in the lungs were counted and
compared with those in the untreated control group. As shown
in Table 8, compound 25a showed potent in vivo activity,
reducing the bacterial burden in the lungs by 2.02 log10 CFU
compared with the untreated control group. In another batch,
TCA1 displayed similar in vivo bactericidal activity compared to
25a, which resulted in a reduction of 2.86 log10 CFU in the
Table 3. continued
aMIC against M. tuberculosis H37Rv.
bSI = selectivity index, IC50/
MIC.
Table 4. Activity of Representative Compounds against Clinical Isolates of M. tuberculosis
MIC (μg/mL)
compounds H37Rv 13946
a 14862b PBTZ169-resistant strain bedaquiline-resistant strain
23j 0.055 0.082 0.059 0.14
24f 0.020 0.031 0.031 0.062 0.054
24j 0.059 0.12 0.12
24k 0.15 0.44 0.23
25a 0.12 0.24 0.24 0.48
25b 0.030 0.062 0.12
25l 0.20 0.94 0.48
TCA1 0.47 0.95 0.48 1.23
INH 0.019 2.46 >10
RFP 0.015 >10 9.24
PBTZ169 0.0001 0.005
bedaquiline 0.036 2.24
aResistance to isoniazid (INH), streptomycin (SM), rifampicin (RFP), ethambutol (EMB), rifabutin (RBT), paza-aminosalicylate (PAS), and
ofloxacin (OFLX). bResistance to INH, SM, RFP, EMB, PAS, prothionamide (1321), and capreomycin (CPM).
Table 5. Activity of Selected Compounds in an Intracellular
Macrophage Infection Model
log10 CFU/macrophages
a
compounds 10 μg/mL Δlog10 CFUb 5 μg/mL Δlog10 CFUb
23j 4.45 ± 0.03 1.07 4.54 ± 0.01 0.98
24f 4.18 ± 0.04 1.34 4.41 ± 0.10 1.11
25a 4.77 ± 0.10 0.75 5.06 ± 0.03 0.46
25b 4.59 ± 0.05 0.93 4.75 ± 0.21 0.77
25l 4.54 ± 0.00 0.98 4.59 ± 0.03 0.93
TCA1 4.36 ± 0.08 1.16 4.91 ± 0.19 0.61
RFP 4.49 ± 0.11 1.03
untreated 5.52 ± 0.18 5.52 ± 0.18
alog10 CFU against M. tuberculosis (H37Rv) in infected mouse J774A.1
macrophages. bΔlog10 CFU = log10 CFU (untreated) − log10 CFU
(treated with the selected compounds).
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lungs. These results showed that compound 25a exhibited
similar potency even at low bioavailability compared to TCA1,
which indicates that further optimization of improving the PK
profiles and therefore enhancing the in vivo efficacy is required.
Target Validation of the Mode of Action. Finally, to
identify and confirm the biological target for this novel
thiophene-arylamide series, the selected compounds with potent
antimycobacterial activities and diversified side chains were
measured against an overexpressed Mt-DprE1 in M. bovis BCG
(Table 9). Compounds 23j, 24f, 24j, 25a, 25b, and 25l showed a
decrease in potency against only DprE1-overexpressing strains
but not against DprE2-overexpressing and wild-type strains.
These compounds, as well as positive control TCA1, displayed a
4-fold higher shift in the MIC when Mt-DprE1 was overex-
pressed in M. bovis BCG. The promising results indicate that
DprE1 could be the target for this novel thiophene-arylamide
series.
To further verify that thiophene-arylamides inhibit the
catalytic activity of DprE1, representative compounds were
tested against M. tuberculosis DprE1. Potent IC50 values in the
range of 0.2−0.9 μg/mL were obtained, showing a good
correlation with the MIC for the compounds tested. These
results confirm a similar mode of action of the thiophene-
arylamides described here to TCA1. Thus, our scaffold hopping
design strategy has resulted in the successful identification of
thiophenes containing the key arylamide moiety as potent
DprE1 inhibitors.
■ CONCLUSIONS
DprE1 has emerged as a promising target for the treatment of
tuberculosis, and previous studies have been indicated that the
inhibition of DprE1 causes loss of its ability to construct the
bacterial cell wall. Based on the crystal structure of the TCA1−
DprE1 complex, we have reported the design, synthesis, and
SAR study of a series of novel thiophene-arylamide compounds.
Molecular docking studies of template compound 23j with
DprE1 indicated that the hydrogen bond interaction with Tyr60
provided additional binding affinity in reinforcing the
Table 6. Hepatocyte Stability, Cytotoxicity, and hERG Inhibition of Selected Compounds
compounds
hepatocyte stability
cytotoxicity (HepG2) hERG K+mouse human
t1/2 (min) %remaining
a t1/2 (min) %remaining
a IC50 (μg/mL) IC50 (μM)
23j 56.4 69.1 50.8 66.4 >64 23.7
24f 43.7 62.1 38.1 58.0 >64 >30
24j 19.3 34.0 72.5 75.1 >64 28.3
25a 27.1 46.5 20.3 35.9 >64 22.6
25b 12.5 19.0 32.6 52.8 >64 >30
TCA1 85.3 74.8 5.97 3.1 46.1 18.3
aSubstrate concentrations were determined in incubations after 30 min and normalized to concentrations at time zero.
Table 7. Mouse PK Properties of Compounds 24f, 25a, and TCA1
24f 25a TCA1
parameters units p.o. i.v. p.o. i.v. p.o. i.v.
dose mg/kg 50 5 50 5 50 5
t1/2
a h 1.70 0.13 0.85 0.26 2.19 0.47
tmax h 1.00 0.58 1.00
Cmax ng/mL 25.4 1299 486 4555 10 603 14 304
AUC0−t ng·h/mL 41.9 183 651 830 33 715 7910
AUC0−∞
b ng·h/mL 57.9 184 657 833 33 724 7912
MRT0−∞
c h 2.10 0.13 1.10 0.20 2.87 0.39
clearance mL/(min·kg) 479 101 10.6
Fd % 2.3 7.9 42.6
aPlasma elimination half-life. bPlasma exposure. cMean residence time. dOral bioavailability.
Table 8. In Vivo Efficacy of Compound 25a
compounds
Dose (mg/
kg)
log10 CFU/
lung
log10 CFU/
lung Δlog10 CFUa
untreated 6.44 ± 0.34 7.10 ± 0.15
INH 25 1.76 ± 0.49 1.93 ± 0.21 4.68/5.17
TCA1 100 4.24 ± 0.25 2.86
25a 100 4.42 ± 0.45 2.02
aΔlog10 CFU = log10 CFU (untreated) − log10 CFU (treated with
selected compounds).
Table 9. Inhibition of DprE1 and Cellular Potency by
Thiophene-arylamides
compounds
MICOE
(μg/mL)a
(DprE1)
MICOE
(μg/mL)b
(DprE2)
MICWT
(μg/mL)c
MIC
foldshiftd
IC50 DprE1
(μg/mL)e
23j >1.28 0.32 0.32 >4 0.3 ± 0.1
24f >0.51 0.13 0.064 >8 0.2 ± 0.04
24j 8.96 0.56 0.28 32 0.3 ± 0.1
25a >12.16 1.52 0.76 >16 0.9 ± 0.2
25b >1.98 0.25 0.12 >16 0.4 ± 0.1
25l 12.8 1.60 1.60 8 0.4 ± 0.1
TCA1 15.36 0.96 0.48 32 0.1 ± 0.01
aOverexpressor (OE) MICs are for Mycobacterium bovis bacillus
Calmette-Guerin (BCG) Pasteur transformed with pMV261:Mt-
dprE1. bOverexpressor (OE) MICs are for M. bovis BCG Pasteur
transformed with pMV261:Mt-dprE2. cMICs against M. bovis BCG
Pasteur strain transformed with pMV261. dRatio of MIC values
against the DprE1-overexpressing strain and wild-type strain. eAll in
vitro assays were performed using Mt-DprE1.
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interaction of thiophene containing the critical benzamide
moiety. Subsequent scaffold hopping from the benzothiazole to
arylamide moiety led to a new series of lead compounds with
improved antimycobacterial activity and low cytotoxicity. In
particular, the representative compounds displayed very potent
activity against both drug-susceptible and drug-resistant tuber-
culosis compared to the target compound TCA1. In addition,
the selected compounds also displayed good inhibition of
intracellular TB growth in infected macrophages. Furthermore,
the preliminary druggability study demonstrated that the
selected compounds exhibited good hepatocyte stability and
low hERG liability. Further biological studies revealed that these
novel thiophene-arylamide compounds targeted DprE1, like
representative compounds 23j, 24f, 25a, and 25b directly bound
to DprE1, and displayed good to excellent DprE1 inhibition.
Importantly, compound 25a with acceptable PK profiles
demonstrated significant efficacy in vivo in an acute mouse
model of TB. Our efforts are ongoing to improve the
druggability profiles of this series of thiophene-arylamide
compounds by maintaining good antituberculosis activity with
the aim of developing more promising candidates as anti-TB
agents targeting DprE1.
■ EXPERIMENTAL SECTION
Chemistry. All reagents and solvents were purchased from
commercial suppliers and used without further purification. Reactions
were monitored by thin-layer chromatography (TLC) with visual-
ization of components by UV light (254 nm) or exposure to I2. Flash
column chromatography was conducted on silica gel (300−400 mesh).
Melting points were determined on a Yanaco MP-J3 microscope
melting point apparatus, which is uncorrected. 1H NMR and 13C NMR
spectra were recorded on Varian-400 and Mercury-500/600
spectrometers in CDCl3 or dimethyl sulfoxide (DMSO)-d6. Electro-
spray ionization-high-resolution mass spectrometry (ESI-HRMS) data
were measured on a Thermo Exactive Orbitrap plus spectrometer.
All target compounds were purified by chromatography and have a
purity of ≥95% as determined by high-performance liquid chromatog-
raphy (HPLC)/MS analysis conducted on a Thermo Exactive Plus
system using a reversed-phase C18 column with 5−95% CH3CN in
water (0.1% HCOOH) for 5 min at a flow rate of 0.4 mL/min.
General Procedure for the Synthesis of Intermediates 3a−p. To a
solution of methyl 4-(chlorocarbonyl)benzoate 1 (1 equiv) in
anhydrous CH2Cl2 were added the corresponding amines 2a−p (1.5
equiv) and Et3N (5 equiv) cooled with an ice bath. The reaction
mixture was stirred at room temperature for 3 h under argon, then
quenched with water, and extracted with CH2Cl2 twice. The combined
organic phase was washed with 1 NHCl, H2O, saturated NaHCO3, and
brine in turn. The obtained organic phase was dried over anhydrous
Na2SO4, filtered, and evaporated in vacuo to give intermediates 3a−p.
Methyl 4-(Propylcarbamoyl)benzoate (3a). White solid; yield
93%; mp 101−102 °C. 1H NMR (400 MHz, CDCl3) δ: 8.09 (d, J = 8.4
Hz, 2H), 7.82 (d, J = 8.4 Hz, 2H), 3.94 (s, 3H), 3.46−3.41 (m, 2H),
1.67−1.65 (m, 2H), 1.00 (t, J = 7.6 Hz, 3H). MS (ESI):m/z 222.11 (M
+ H)+.
Methyl 4-(Ethyl(methyl)carbamoyl)benzoate (3b). White solid;
yield 92%; mp 50−51 °C. 1H NMR (400 MHz, CDCl3) δ: 8.08 (d, J =
8.4 Hz, 2H), 7.46 (d, J = 8.4 Hz, 2H), 3.94 (s, 3H), 3.24−2.91 (m, 2H),
1.26−1.23 (m, 3H). MS (ESI): m/z 222.11 (M + H)+.
Methyl 4-(Diethylcarbamoyl)benzoate (3c). White solid; yield
94%; mp 154−155 °C. 1H NMR (400 MHz, CDCl3) δ: 8.08 (d, J = 8.4
Hz, 2H), 7.44 (d, J = 8.4 Hz, 2H), 3.94 (s, 3H), 3.56 (brs, 2H), 3.22
(brs, 2H), 1.26 (brs, 3H), 1.10 (brs, 3H). MS (ESI): m/z 236.13 (M +
H)+.
Methyl 4-(((3S,5S,7S)-Adamantan-1-yl)carbamoyl)benzoate
(3d). White solid; yield 98%; mp 182−183 °C. 1H NMR (400 MHz,
CDCl3) δ: 8.07 (d, J = 8.4 Hz, 2H), 7.77 (d, J = 8.4 Hz, 2H), 3.94 (s,
3H), 2.13 (brs, 9H), 1.73 (brs, 6H). MS (ESI): m/z 314.17 (M + H)+.
Methyl 4-(Cyclohexylcarbamoyl)benzoate (3e).White solid; yield
91%; mp 199−200 °C. 1H NMR (500 MHz, CDCl3) δ: 8.09 (d, J = 8.0
Hz, 2H), 7.80 (d, J = 8.0 Hz, 2H), 6.00 (brs, 1H), 3.98 (m, 1H), 3.94 (s,
3H), 2.06−2.03 (m, 2H), 1.78−1.75 (m, 2H), 1.68−1.66 (m, 1H),
1.45−1.40 (m, 2H), 1.29−1.24 (m, 3H). MS (ESI): m/z 262.14 (M +
H)+.
Methyl 4-((4,4-Dimethylcyclohexyl)carbamoyl)benzoate (3f).
White solid; yield 95%; mp 106−107 °C. 1H NMR (400 MHz,
CDCl3) δ: 8.09 (d, J = 8.8 Hz, 2H), 7.81 (d, J = 8.8 Hz, 2H), 6.06−6.04
(m, 1H), 3.94 (m, 4H), 1.92−1.88 (m, 2H), 1.46−1.39 (m, 6H), 0.95
(s, 6H). MS (ESI): m/z 290.18 (M + H)+.
Methyl 4-(Phenylcarbamoyl)benzoate (3g). White solid; yield
91%; mp 189−190 °C. 1H NMR (400 MHz, DMSO-d6) δ: 10.45 (brs,
1H), 8.11−8.06 (m, 4H), 7.80−7.77 (m, 2H), 7.39−7.35 (m, 2H),
7.14−7.10 (m, 1H), 3.90 (s, 3H). MS (ESI): m/z 256.10 (M + H)+.
Methyl 4-(Azetidine-1-carbonyl)benzoate (3h). White solid; yield
94%; mp 88−89 °C. 1H NMR (400 MHz, CDCl3) δ: 8.07 (d, J = 8.8
Hz, 2H), 7.68 (d, J = 8.8 Hz, 2H), 4.31−4.22 (m, 4H), 3.94 (s, 3H),
2.40−2.33 (m, 2H). MS (ESI): m/z 220.09 (M + H)+.
Methyl 4-(Pyrrolidine-1-carbonyl)benzoate (3i).White solid; yield
95%; mp 103−104 °C. 1H NMR (400 MHz, CDCl3) δ: 8.07 (d, J = 8.4
Hz, 2H), 7.57 (d, J = 8.4 Hz, 2H), 3.94 (s, 3H), 3.64 (brs, 2H), 3.40
(brs, 2H) 1.93 (brs, 4H). MS (ESI): m/z 234.11 (M + H)+.
Methyl 4-(Piperidine-1-carbonyl)benzoate (3j). White solid; yield
92%; mp 127−128 °C. 1H NMR (500 MHz, CDCl3) δ: 8.07 (d, J = 8.0
Hz, 2H), 7.45 (d, J = 8.0 Hz, 2H), 3.93 (s, 3H), 3.72 (brs, 2H), 3.29
(brs, 2H), 1.69 (brs, 4H), 1.52 (brs, 2H). MS (ESI): m/z 248.13 (M +
H)+.
Methyl 4-(Azepane-1-carbonyl)benzoate (3k). Colorless oil; yield
99%; 1HNMR (400MHz, CDCl3) δ: 8.07 (d, J = 8.4Hz, 2H), 7.44 (d, J
= 8.4 Hz, 2H), 3.93 (s, 3H), 3.69 (t, J = 6.0 Hz, 2H), 3.32 (brs, 2H),
1.88−1.82 (m, 2H), 1.65 (brs, 2H), 1.60 (brs, 4H). MS (ESI): m/z
262.14 (M + H)+.
Methyl 4-(4-Methylpiperidine-1-carbonyl)benzoate (3l).Colorless
oil; yield 95%; 1HNMR (400MHz, CDCl3) δ: 8.07 (d, J = 8.4 Hz, 2H),
7.45 (d, J = 8.4 Hz, 2H), 4.69−4.67 (m, 1H), 3.93 (s, 3H), 3.62−3.59
(m, 1H), 2.99 (brs, 1H), 2.78 (brs, 1H), 1.76 (brs, 1H), 1.72−1.61 (m,
2H), 1.26−1.07 (m, 2H), 0.98 (d, J = 6.4 Hz, 3H). MS (ESI): m/z
262.14 (M + H)+.
Methyl 4-(4-Methoxypiperidine-1-carbonyl)benzoate (3m). Light
yellow oil; yield 99%; 1H NMR (500 MHz, CDCl3) δ: 8.08 (d, J = 8.0
Hz, 2H), 7.45 (d, J = 8.0 Hz, 2H), 4.01 (brs, 1H), 3.94 (s, 3H), 3.55
(brs, 2H), 3.50−3.49 (m, 1H), 3.37 (s, 3H), 3.18 (brs, 1H), 1.95 (brs,
1H), 1.78−1.72 (m, 2H), 1.56 (brs, 1H). MS (ESI): m/z 278.14 (M +
H)+.
Methyl 4-(4,4-Difluoropiperidine-1-carbonyl)benzoate (3n).
White solid; yield 97%; mp 83−84 °C. 1H NMR (400 MHz, CDCl3)
δ: 8.11 (d, J = 8.4 Hz, 2H), 7.48 (d, J = 8.4 Hz, 2H), 3.95 (s, 3H), 3.88
(brs, 2H), 3.51 (brs, 2H), 2.45−2.33 (m, 1H), 2.08−1.95 (m, 3H). MS
(ESI): m/z 284.11 (M + H)+.
Methyl 4-(Morpholine-4-carbonyl)benzoate (3o). White solid;
yield 98%; mp 79−80 °C.1H NMR (400 MHz, CDCl3) δ: 8.07 (d, J =
8.4 Hz, 2H), 7.46 (d, J = 8.4 Hz, 2H), 3.92 (s, 3H), 3.81−3.74 (m, 4H),
3.61 (brs, 2H), 3.38 (brs, 2H). MS (ESI): m/z 250.11 (M + H)+.
Methyl 4-(Thiomorpholine-4-carbonyl)benzoate (3p). White
solid; yield 93%; mp 101−102 °C. 1H NMR (500 MHz, CDCl3) δ:
8.09 (d, J = 8.0 Hz, 2H), 7.44 (d, J = 8.0 Hz, 2H), 4.04 (brs, 2H) 3.94 (s,
3H), 3.62 (brs, 2H), 2.75 (brs, 2H), 2.56 (brs, 2H). MS (ESI): m/z
266.08 (M + H)+.
General Procedure for the Synthesis of Intermediates 4a−p. To a
solution of 3a−p (1 equiv) in CH3OH was added 1 mol/L LiOH
aqueous solution (2 equiv). The reaction mixture was stirred at room
temperature for 3 h and then evaporated in vacuo. The residue was
diluted with H2O, and the aqueous solution was acidified with 6 NHCl
to pH 6−7. The precipitated solid was filtered to afford intermediates
4a−p.
4-(Propylcarbamoyl)benzoic Acid (4a).White solid; yield 91%; mp
233−234 °C. 1H NMR (400 MHz, DMSO-d6) δ: 13.18 (brs, 1H), 8.61
(brs, 1H), 8.00 (d, J = 8.4 Hz, 2H), 7.92 (d, J = 8.4 Hz, 2H), 3.25−3.20
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(m, 2H), 1.58−1.49 (m, 2H), 0.89 (t, J = 7.6 Hz, 3H). MS (ESI): m/z
206.08 (M − H)−.
4-(Ethyl(methyl)carbamoyl)benzoic Acid (4b). White solid; yield
46%; mp 177−178 °C. 1H NMR (400 MHz, DMSO-d6) δ: 13.11 (brs,
1H), 8.00−7.97 (m, 2H), 7.49−7.46 (m, 2H), 3.49−3.45 (m, 1H),
3.18−3.13 (m, 1H), 2.96−2.84 (m, 3H), 1.14−1.03 (m, 3H). MS
(ESI): m/z 206.08 (M − H)−.
4-(Diethylcarbamoyl)benzoic Acid (4c).White solid; yield 56%;mp
154−155 °C. 1H NMR (500 MHz, DMSO-d6) δ: 13.10 (brs, 1H), 7.99
(d, J = 8.0 Hz, 2H), 7.45 (d, J = 8.0 Hz, 2H), 3.44 (brs, 2H), 3.14 (brs,
2H), 1.15 (brs, 3H), 1.03 (brs, 3H). MS (ESI):m/z 220.10 (M−H)−.
4-(((3S,5S,7S)-Adamantan-1-yl)carbamoyl)benzoic Acid (4d).
White solid; yield 93%; mp 245−246 °C. 1H NMR (400 MHz,
DMSO-d6) δ: 13.18 (brs, 1H), 7.96 (d, J = 8.4 Hz, 2H), 7.85 (d, J = 8.4
Hz, 2H), 7.80 (brs, 1H), 2.07 (brs, 9H), 1.65 (brs, 6H). MS (ESI):m/z
298.15 (M − H)−.
4-(Cyclohexylcarbamoyl)benzoic Acid (4e). White solid; yield
97%;mp > 250 °C. 1HNMR (500MHz, DMSO-d6) δ: 13.16 (brs, 1H),
8.37 (d, J = 8.0 Hz, 1H), 7.99 (d, J = 8.0 Hz, 2H), 7.92 (d, J = 8.0 Hz,
2H), 3.76 (brs, 1H), 1.81 (brs, 2H), 1.74 (brs, 2H), 1.62−1.59 (m, 1H),
1.31−1.23 (m, 4H), 1.13−1.12 (m, 1H). MS (ESI): m/z 246.12 (M −
H)−.
4-((4,4-Dimethylcyclohexyl)carbamoyl)benzoic Acid (4f). White
solid; yield 90%; mp > 250 °C. 1HNMR (400MHz, DMSO-d6) δ: 8.38
(d, J = 8.0 Hz, 1H), 7.99 (d, J = 8.4 Hz, 2H), 7.93 (d, J = 8.4 Hz, 2H),
3.77−3.67 (m, 1H), 1.65−1.61 (m, 2H), 1.56−1.52 (m, 2H), 1.41−
1.38 (m, 2H), 1.29−1.23 (m, 2H), 0.93 (brs, 3H), 0.92 (brs, 3H). MS
(ESI): m/z 274.15 (M − H)−.
4-(Phenylcarbamoyl)benzoic Acid (4g).White solid; yield 72%; mp
> 250 °C. 1H NMR (400 MHz, DMSO-d6) δ: 13.25 (brs, 1H), 10.42
(brs, 1H),8.09−8.04 (m, 4H), 7.90 (d, J = 8.0 Hz, 2H), 7.36 (t, J = 8.0
Hz, 2H), 7.12 (t, J = 7.4 Hz, 1H). MS (ESI): m/z 240.07 (M − H)−.
4-(Azetidine-1-carbonyl)benzoic Acid (4h).White solid; yield 78%;
mp 213−215 °C. 1H NMR (400 MHz, DMSO-d6) δ: 13.19 (brs, 1H),
7.90 (d, J = 8.4 Hz, 2H), 7.10 (d, J = 8.4 Hz, 2H), 4.27 (t, J = 7.6 Hz,
2H), 4.05 (t, J = 7.6 Hz, 2H), 2.29−2.21 (m, 2H). MS (ESI): m/z
204.07 (M − H)−.
4-(Pyrrolidine-1-carbonyl)benzoic Acid (4i). White solid; yield
89%; mp 219−220 °C. 1H NMR (400 MHz, DMSO-d6) δ: 13.14 (brs,
1H), 7.98 (d, J = 8.4 Hz, 2H), 7.60 (d, J = 8.4 Hz, 2H), 3.47 (t, J = 6.8
Hz, 2H), 3.33 (t, J = 6.4 Hz, 2H), 1.88−1.79 (m, 4H). MS (ESI): m/z
218.08 (M − H)−.
4-(Piperidine-1-carbonyl)benzoic Acid (4j).White solid; yield 89%;
mp 240−241 °C. 1H NMR (500 MHz, DMSO-d6) δ: 13.11 (brs, 1H),
7.98 (d, J = 8.0 Hz, 2H), 7.47 (d, J = 8.0 Hz, 2H), 3.59 (brs, 2H), 3.21
(brs, 2H), 1.60−1.56 (m, 4H), 1.44 (brs, 2H). MS (ESI): m/z 232.10
(M − H)−.
4-(Azepane-1-carbonyl)benzoic Acid (4k).White solid; yield 92%;
mp 238−239 °C. 1H NMR (400 MHz, DMSO-d6) δ: 13.10 (brs, 1H),
7.98 (d, J = 8.4 Hz, 2H), 7.46 (d, J = 8.4 Hz, 2H), 3.56 (t, J = 6.0 Hz,
2H), 3.25 (t, J = 5.6 Hz, 2H), 1.73−1.70 (m, 2H), 1.58−1.55 (m, 2H),
1.64−1.48 (m, 4H). MS (ESI): m/z 246.11 (M − H)−.
4-(4-Methylpiperidine-1-carbonyl)benzoic Acid (4l). White solid;
yield 92%; mp 196−197 °C. 1H NMR (500 MHz, DMSO-d6) δ: 13.12
(brs, 1H), 7.98 (d, J = 8.0 Hz, 2H), 7.47 (d, J = 8.0 Hz, 2H), 4.45−4.43
(m, 1H), 3.45−3.43 (m, 1H), 3.00 (brs, 1H), 2.76 (brs, 1H), 1.69−1.53
(m, 3H), 1.08−1.05 (m, 2H), 0.92 (d, J = 6.0 Hz, 3H). MS (ESI): m/z
246.11 (M − H)−.
4-(4-Methoxypiperidine-1-carbonyl)benzoic Acid (4m). White
solid; yield 49%. mp 184−185 °C. 1H NMR (400 MHz, DMSO-d6)
δ: 13.13 (brs, 1H), 7.98 (d, J = 8.4 Hz, 2H), 7.49 (d, J = 8.4 Hz, 2H),
3.91 (brs, 1H), 3.45−3.42 (m, 3H), 3.25 (s, 3H), 3.11 (brs, 1H), 1.87−
1.77 (m, 2H), 1.47−1.40 (m, 2H). MS (ESI): m/z 262.11 (M − H)−.
4-(4,4-Difluoropiperidine-1-carbonyl)benzoic Acid (4n). White
solid; yield 83%; mp 228−229 °C. 1H NMR (400 MHz, DMSO-d6)
δ: 13.14 (brs, 1H), 8.00 (d, J = 8.4 Hz, 2H), 7.56 (d, J = 8.4 Hz, 2H),
3.73 (brs, 2H), 3.37 (brs, 2H), 2.03 (brs, 4H). MS (ESI): m/z 268.08
(M − H)−.
4-(Morpholine-4-carbonyl)benzoic Acid (4o). White solid; yield
76%; mp 194−195 °C. 1H NMR (400 MHz, DMSO-d6) δ: 13.16 (brs,
1H), 7.99 (d, J = 8.4 Hz, 2H), 7.52 (d, J = 8.4 Hz, 2H), 3.64 (brs, 4H),
3.54 (brs, 2H), 3.29 (brs, 2H). MS (ESI): m/z 234.08 (M − H)−.
4-(Thiomorpholine-4-carbonyl)benzoic Acid (4p). White solid;
yield 82%;mp > 250 °C. 1HNMR (400MHz, DMSO-d6) δ: 13.14 (brs,
1H), 7.99 (d, J = 8.4 Hz, 2H), 7.50 (d, J = 8.4 Hz, 2H), 3.87 (brs, 2H),
3.49 (brs, 2H), 2.69 (brs, 2H), 2.59 (brs, 2H). MS (ESI): m/z 250.05
(M − H)−.
General Procedure for the Synthesis of Intermediates 6a−l. To a
solution of aryl carboxylic acids 5a−l (1 equiv) in DMF were added
HATU (2 equiv), piperidine (1.5 equiv), and Et3N (3 equiv). The
reaction mixture was stirred at room temperature for 10 h and then
concentrated in vacuo. The residue was diluted with CH2Cl2, washed
with water and brine, dried over anhydrous Na2SO4, filtered, and
evaporated in vacuo. The residue was purified by silica gel column
chromatography (petroleum ether (PE)/ethyl acetate (EA) = 100/30)
to afford intermediates 6a−l.
Methyl 3-(Piperidine-1-carbonyl)benzoate (6a). Colorless oil;
yield 63%. 1H NMR (500 MHz, CDCl3) δ: 8.07 (brs, 2H), 7.60−
7.59 (m, 1H), 7.51−7.48 (m, 1H), 3.93 (s, 3H), 3.72 (brs, 2H), 3.33
(brs, 2H), 1.69 (brs, 4H), 1.53 (brs, 2H).
Methyl 2-Fluoro-4-(piperidine-1-carbonyl)benzoate (6b). White
solid; yield 90%;. 1H NMR (400 MHz, CDCl3) δ: 7.98 (t, J = 7.6 Hz,
1H), 7.21 (dd, J1 = 8.0 Hz, J2 = 1.6 Hz, 1H), 7.17 (dd, J1 = 10.8 Hz, J2 =
1.6 Hz, 1H), 3.95 (s, 3H), 3.70 (brs, 2H), 3.29 (brs, 2H), 1.69 (brs,
4H), 1.53 (brs, 2H).
Methyl 2-Chloro-4-(piperidine-1-carbonyl)benzoate (6c). Yellow
oil; yield 95%. 1HNMR (400MHz, CDCl3) δ: 7.84 (d, J = 8.0 Hz, 1H),
7.45 (d, J = 1.6 Hz, 1H), 7.29 (dd, J1 = 8.0 Hz, J2 = 1.6 Hz, 1H), 3.93 (s,
3H), 3.68 (brs, 2H), 3.28 (brs, 2H), 1.67 (brs, 4H), 1.50 (brs, 2H). MS
(ESI): m/z 282.09 (M + H)+.
Methyl 2-Bromo-4-(piperidine-1-carbonyl)benzoate (6d). Color-
less oil; yield 75%. 1H NMR (400 MHz, CDCl3) δ: 7.82 (d, J = 7.6 Hz,
1H), 7.68 (d, J = 1.6 Hz, 1H), 7.36 (dd, J1 = 8.0 Hz, J2 = 1.6 Hz, 1H),
3.95 (s, 3H), 3.70 (brs, 2H), 3.30 (brs, 2H), 1.69 (brs, 4H), 1.53 (brs,
2H). MS (ESI): m/z 326.04 (M + H)+.
Methyl 2-Nitro-4-(piperidine-1-carbonyl)benzoate (6e). White
solid; yield 97%; mp 73−74 °C. 1H NMR (400 MHz, CDCl3) δ:
7.94−7.93 (m, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.70 (dd, J1 = 8.0 Hz, J2 =
1.6 Hz, 1H), 3.94 (s, 3H), 3.73 (brs, 2H), 3.33 (brs, 2H), 1.71 (brs,
4H), 1.62−1.56 (m, 2H). MS (ESI): m/z 293.11 (M + H)+.
Methyl 3-Fluoro-4-(piperidine-1-carbonyl)benzoate (6f). White
solid; yield 93%; mp 64−65 °C. 1H NMR (400 MHz, CDCl3) δ: 7.88
(dd, J1 = 8.0 Hz, J2 = 1.6 Hz, 1H), 7.76 (dd, J1 = 9.6 Hz, J2 = 1.6 Hz, 1H),
7.43 (dd, J1 = 8.0 Hz, J2 = 2.4 Hz, 1H), 3.94 (s, 3H), 3.74 (brs, 2H), 3.23
(brs, 2H), 1.69−1.67 (m, 4H), 1.53 (brs, 2H). MS (ESI): m/z 266.12
(M + H)+.
Methyl 3-Methyl-4-(piperidine-1-carbonyl)benzoate (6g). White
solid; yield 90%; mp 77−78 °C. 1H NMR (400 MHz, CDCl3) δ: 7.90
(brs, 1H), 7.88 (dd, J1 = 8.0 Hz, J2 = 1.6 Hz, 1H), 7.23 (d, J = 8.0 Hz,
1H), 3.92 (s, 3H), 3.83−3.80 (m, 1H), 3.71−3.68 (m, 1H), 3.15−3.12
(m, 2H), 2.36 (s, 3H), 1.67 (brs, 4H), 1.47 (brs, 2H). MS (ESI): m/z
262.14 (M + H)+.
Methyl 6-(Piperidine-1-carbonyl)-2-naphthoate (6h).White solid;
yield 79%; mp 127−128 °C. 1H NMR (400 MHz, CDCl3) δ: 8.61 (s,
1H), 8.10 (dd, J1 = 8.0 Hz, J2 = 1.6 Hz, 1H), 7.98 (d, J = 8.0 Hz, 1H),
7.92−7.90 (m, 2H), 7.54 (dd, J1 = 8.0Hz, J2 = 1.6Hz, 1H), 3.99 (s, 3H),
3.81 (brs, 2H), 3.39 (brs, 2H), 1.71 (brs, 4H), 1.56 (brs, 2H). MS
(ESI): m/z 298.14 (M + H)+.
Methyl 4′-(Piperidine-1-carbonyl)-[1,1′-biphenyl]-4-carboxylate
(6i). White solid; yield 91%; mp 114−115 °C. 1H NMR (400 MHz,
DMSO-d6) δ: 8.05 (d, J = 7.6 Hz, 2H), 7.87 (d, J = 7.6 Hz, 2H), 7.81 (d,
J = 7.6 Hz, 2H), 7.49 (d, J = 7.6 Hz, 2H), 3.88 (s, 3H), 3.60 (brs, 2H),
3.26 (brs, 2H), 1.62 (brs, 2H), 1.53 (brs, 4H). MS (ESI): m/z 324.16
(M + H)+.
Methyl 5-(Piperidine-1-carbonyl)thiophene-2-carboxylate (6j).
White solid; yield 92%; mp 83−84 °C. 1H NMR (400 MHz, CDCl3)
δ: 7.70 (dd, J1 = 8.0 Hz, J2 = 1.2 Hz, 1H), 7.20 (dd, J1 = 8.0 Hz, J2 = 1.2
Hz, 1H), 3.91 (s, 3H), 3.64 (brs, 4H), 1.71−1.70 (brs, 2H), 1.65−1.64
(brs, 4H). MS (ESI): m/z 254.08 (M + H)+.
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Methyl 5-(Piperidine-1-carbonyl)furan-3-carboxylate (6k). White
solid; yield 74%; mp 79−80 °C. 1H NMR (400 MHz, CDCl3) δ: 8.03
(s, 1H), 7.15 (s, 1H), 3.86 (s, 3H), 3.69−3.66 (m, 4H), 1.71−1.69 (m,
2H), 1.67−1.63 (m, 4H). MS (ESI): m/z 238.11 (M + H)+.
Methyl 4-(Piperidine-1-carbonyl)-1H-pyrrole-2-carboxylate (6l).
White solid; yield 53%; mp 105−106 °C. 1H NMR (400 MHz, CDCl3)
δ: 9.87 (brs, 1H), 6.87 (dd, J1 = 4.0 Hz, J2 = 2.8 Hz, 1H), 6.46 (dd, J1 =
4.0 Hz, J2 = 2.8 Hz, 1H), 3.87 (s, 3H), 3.74 (brs, 4H), 1.72−1.69 (m,
2H), 1.67−1.63 (m, 4H). MS (ESI): m/z 237.12 (M + H)+.
General Procedure for the Synthesis of Intermediates 7a−l.
Compounds 7a−l were prepared from 6a−l in the same manner as
described for 4a−p.
3-(Piperidine-1-carbonyl)benzoic Acid (7a). White solid; yield
59%; mp 123−124 °C. 1H NMR (500 MHz, DMSO-d6) δ: 13.16 (brs,
1H), 7.99 (brs, 1H), 7.87 (brs, 1H), 7.61−7.57 (m, 2H), 3.59 (brs, 2H),
3.25 (brs, 2H), 1.61−1.56 (m, 4H), 1.46 (brs, 2H). MS (ESI): m/z
232.08 (M − H)−.
2-Fluoro-4-(piperidine-1-carbonyl)benzoic Acid (7b).White solid;
yield 97%; mp 202−203 °C. 1H NMR (400 MHz, DMSO-d6) δ: 13.41
(brs, 1H), 7.91 (dd, J1 = 7.6 Hz, J2 = 1.2 Hz, 1H), 7.73 (dd, J1 = 9.6 Hz,
J2 = 1.2 Hz, 1H), 7.27 (dd, J1 = 7.6 Hz, J2 = 2.8 Hz, 1H), 3.58 (brs, 2H),
3.21 (m, 2H), 1.61−1.56 (m, 4H), 1.45 (brs, 2H). MS (ESI): m/z
250.11 (M − H)−.
2-Chloro-4-(piperidine-1-carbonyl)benzoic Acid (7c).White solid;
yield 70%; mp 162−163 °C. 1H NMR (400 MHz, DMSO-d6) δ: 13.53
(brs, 1H), 7.83 (d, J = 7.6 Hz, 1H), 7.53 (d, J = 1.6 Hz, 1H), 7.40 (dd, J1
= 8.0 Hz, J2 = 1.6 Hz, 1H), 3.57 (brs, 2H), 3.22 (brs, 2H), 1.60−1.56
(m, 4H), 1.45 (brs, 2H). MS (ESI): m/z 266.06 (M − H)−.
2-Bromo-4-(piperidine-1-carbonyl)benzoic Acid (7d).White solid;
yield 64%; mp 175−176 °C. 1H NMR (400 MHz, DMSO-d6) δ: 13.50
(brs, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.64 (d, J = 1.2 Hz, 1H), 7.40 (dd, J1
= 8.0 Hz, J2 = 1.2 Hz, 1H), 3.53 (brs, 2H), 3.19 (brs, 2H), 1.57−1.50
(m, 4H), 1.42 (brs, 2H). MS (ESI): m/z 310.01 (M − H)−.
2-Nitro-4-(piperidine-1-carbonyl)benzoic Acid (7e). White solid;
yield 88%; mp 90−91 °C. 1HNMR (400MHz, DMSO-d6) δ: 7.99 (d, J
= 1.2 Hz, 1H), 7.91 (d, J = 7.6 Hz, 1H), 7.72 (dd, J1 = 7.6 Hz, J2 = 1.2
Hz, 1H), 3.59 (brs, 2H), 3.23 (brs, 2H), 1.59 (brs, 4H), 1.47 (brs, 2H).
MS (ESI): m/z 277.09 (M − H)−.
3-Fluoro-4-(piperidine-1-carbonyl)benzoic Acid (7f). White solid;
yield 98%; mp 202−203 °C. 1H NMR (400 MHz, DMSO-d6) δ: 13.38
(brs, 1H), 7.88 (dd, J1 = 7.6 Hz, J2 = 1.2 Hz, 1H), 7.69 (dd, J1 = 9.6 Hz,
J2 = 1.2 Hz, 1H), 7.47 (dd, J1 = 7.6 Hz, J2 = 2.8 Hz, 1H), 3.59−3.56 (m,
2H), 3.13−3.11 (m, 2H), 1.58−1.51 (m, 4H), 1.42−1.37 (m, 2H). MS
(ESI): m/z 250.09 (M − H)−.
3-Methyl-4-(piperidine-1-carbonyl)benzoic Acid (7g).White solid;
yield 82%; mp 146−147 °C. 1H NMR (500 MHz, DMSO-d6) δ: 13.00
(brs, 1H), 7.83 (brs, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.26 (d, J = 8.0 Hz,
1H), 3.67−3.57 (m, 2H), 3.06−3.05 (m, 2H), 2.25 (s, 3H), 1.60−1.55
(m, 4H), 1.40−1.37 (m, 2H). MS (ESI): m/z 246.10 (M − H)−.
6-(Piperidine-1-carbonyl)-2-naphthoic Acid (7h). White solid;
yield 91%; mp 181−182 °C. 1H NMR (500 MHz, DMSO-d6) δ:
13.19 (brs, 1H), 8.64 (s, 1H), 8.19−8.17 (m, 1H), 8.09−8.08 (m, 1H),
8.03−8.02 (m, 2H), 7.57−7.55 (m, 1H), 3.64 (brs, 2H), 3.30 (brs, 2H),
1.62 (brs, 4H), 1.47 (brs, 2H). MS (ESI): m/z 282.10 (M − H)−.
4′-(Piperidine-1-carbonyl)-[1,1′-biphenyl]-4-carboxylic Acid (7i).
White solid; yield 53%; mp 247−248 °C. 1HNMR (500MHz, DMSO-
d6) δ: 13.03 (brs, 1H), 8.03 (d, J = 8.0Hz, 2H), 7.84 (d, J = 8.0Hz, 2H),
7.89 (d, J = 8.0 Hz, 2H), 7.48 (d, J = 8.0 Hz, 2H), 3.60 (brs, 2H), 3.20
(brs, 2H), 1.62−1.47 (m, 6H). MS (ESI): m/z 308.12 (M − H)−.
5-(Piperidine-1-carbonyl)thiophene-2-carboxylic Acid (7j). White
solid; yield 90%; mp 183−184 °C. 1H NMR (500 MHz, DMSO-d6) δ:
13.36 (brs, 1H), 7.66 (d, J = 3.5 Hz, 1H), 7.34 (d, J = 3.5 Hz, 1H),
3.56−3.54 (m, 4H), 1.63−1.62 (m, 2H), 1.54−1.53 (m, 4H). MS
(ESI): m/z 238.04 (M − H)−.
5-(Piperidine-1-carbonyl)furan-3-carboxylic Acid (7k). White
solid; yield 50%; mp 169−170 °C. 1H NMR (500 MHz, DMSO-d6)
δ: 13.01 (brs, 1H), 8.41 (s, 1H), 7.06 (s, 1H), 3.57(brs, 4H), 1.66−1.60
(brs, 2H), 1.56−1.53 (brs, 4H). MS (ESI): m/z 222.06 (M − H)−.
4-(Piperidine-1-carbonyl)-1H-pyrrole-2-carboxylic Acid (7l).
White solid; yield 86%; mp 228−229 °C. 1H NMR (500 MHz,
DMSO-d6) δ: 12.50 (brs, 1H), 11.87 (brs, 1H), 6.71 (s, 1H), 6.35(s,
1H), 3.53 (brs, 4H), 1.62 (brs, 2H), 1.51 (m, 4H). MS (ESI): m/z
221.08 (M − H)−.
Procedure for the Synthesis of Intermediate 9. To a solution of
compound 8 (1.00 g, 6.36 mmol) and (Boc)2O (1.50 g, 9.54 mmol) in
CH2Cl2 (100 mL) were added DMAP (0.08 g, 0.64 mmol) and Et3N
(1.29 g, 12.72 mmol). The reaction mixture was stirred under argon at
room temperature for 6 h and then quenched with water (100mL). The
organic phase was washed with brine, dried over anhydrous Na2SO4,
filtered, and evaporated in vacuo. The residue was purified by silica gel
column chromatography (PE/EA = 100/20) to give intermediate 9.
Methyl 2-((tert-Butoxycarbonyl)amino)thiophene-3-carboxylate
(9). Yellow oil; yield 34%. 1HNMR (500MHz, DMSO-d6) δ: 9.95 (brs,
1H), 7.12 (d, J = 5.5 Hz, 1H), 6.97 (d, J = 6.0 Hz, 1H), 3.81 (s, 3H),
1.50 (s, 9H).
Procedure for the Synthesis of Intermediate 10. To a solution of 9
(2.00 g, 7.77 mmol) in CH3OH (100 mL) was added 1 mol/L NaOH
aqueous solution (20 mL). The reaction mixture was heated to reflux
for 4 h. After cooling to room temperature, the solution was acidified
with 1 N HCl aqueous solution to pH 2 at 0 °C, and the precipitated
solid was filtered to afford intermediate 10.
2-((tert-Butoxycarbonyl)amino)thiophene-3-carboxylic Acid
(10). White solid; yield 63%; mp 174−175 °C. 1H NMR (500 MHz,
DMSO-d6) δ: 13.13 (brs, 1H), 10.15 (brs, 1H), 7.10 (d, J = 5.5Hz, 1H),
6.93 (d, J = 6.0 Hz, 1H), 1.50 (s, 9H).
General Procedure for the Synthesis of Intermediates 11a and
11b. To a solution of compound 10 (1 equiv) and alicyclic amines (1.1
equiv) in anhydrous DMF were added EDCI (1.1 equiv), HOBt (1.1
equiv), and Et3N (1.1 equiv) in turn. The reaction mixture was stirred
under argon at room temperature for 12 h. The reaction mixture was
quenched with water and extracted with ethyl acetate twice. The
combined organic phase was washed with brine, dried over anhydrous
Na2SO4, filtered, and evaporated in vacuo. The residue was purified by
silica gel column chromatography (CH2Cl2/MeOH = 100/1) to give
intermediates with N-Boc. The above intermediates (1.36 mmol) and
trifluoroacetic acid (4 mL) were dissolved in CH2Cl2 (12 mL). The
reaction mixture was stirred at room temperature for 2.5 h and then
poured into water (15 mL). The aqueous phase was separated and
basified with K2CO3 to pH 7−8. The precipitated solid was filtered to
obtain intermediates 11a and 11b.
Methyl 1-(2-Aminothiophene-3-carbonyl)azetidine-3-carboxy-
late (11a). Brown oil; yield 11%. 1H NMR (400 MHz, DMSO-d6) δ:
7.33 (brs, 2H), 6.76 (d, J = 6.0 Hz, 1H), 6.27 (d, J = 5.6 Hz, 1H), 4.23−
4.18 (m, 4H), 3.67 (s, 3H), 3.57−3.49 (m, 1H).
Methyl 1-(2-Aminothiophene-3-carbonyl)piperidine-4-carboxy-
late (11b). Black oil; yield 50%. 1H NMR (500 MHz, DMSO-d6) δ:
6.63 (d, J = 5.5 Hz, 1H), 6.36 (brs, 2H), 6.32 (d, J = 5.5 Hz, 1H), 4.00
(d, J = 13.0 Hz, 2H), 3.61 (s, 3H), 2.97 (t, J = 12.0 Hz, 2H), 2.62 (t, J =
11.0 Hz, 1H), 1.85 (d, J = 11.0 Hz, 2H), 1.55−1.47 (m, 2H).
General Procedure for the Synthesis of Intermediates 11c and
11d. To a solution of compound 12 (1 equiv) and alicyclic amines (1.1
equiv) in anhydrous DMF were added EDCI (1.1 equiv), HOBt (1.1
equiv), and Et3N (1.1 equiv) in turn. The reaction mixture was stirred
under argon at room temperature for 12 h. The reaction mixture was
quenched with water and extracted with ethyl acetate twice. The
combined organic phase was washed with brine, dried over anhydrous
Na2SO4, filtered, and evaporated in vacuo. The residue was purified by
silica gel column chromatography (CH2Cl2/MeOH = 100/1) to give
intermediates 11c and 11d.
Methyl 4-(2-Aminothiophene-3-carbonyl)piperazine-1-carboxy-
late (11c). Purple oil; yield 49%. 1H NMR (500 MHz, DMSO-d6) δ:
6.66 (d, J = 6.0Hz, 1H), 6.46 (brs, 2H), 6.34 (d, J = 6.0Hz, 1H), 3.61 (s,
3H), 3.47 (brs, 4H), 3.41 (brs, 4H).
Ethyl 4-(2-Aminothiophene-3-carbonyl)piperazine-1-carboxy-
late (11d). Brown oil; yield 46%. 1H NMR (500 MHz, DMSO-d6) δ:
6.66 (d, J = 4.0 Hz, 1H), 6.46 (brs, 2H), 6.34 (d, J = 3.5 Hz, 1H), 4.06
(d, J = 6.5 Hz, 2H), 3.47 (brs, 4H), 3.41 (brs, 4H), 1.19 (brs, 3H).
Procedure for the Synthesis of Intermediate 12. To a solution of
methyl 2-aminothiophene-3-carboxylate 8 (1.22 g, 7.77 mmol) in
CH3OH (25 mL) was added 1 mol/L NaOH aqueous solution (15
mL). The reaction mixture was heated to reflux for 4 h. After cooling to
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room temperature, the solution was acidified with 1 N HCl solution to
pH 2 at 0 °C and the precipitated solid was filtered to afford
intermediate 12.
2-Aminothiophene-3-carboxylic Acid (12). Brown solid; yield 62%;
mp 138−140 °C. 1H NMR (400 MHz, DMSO-d6) δ: 11.82 (brs, 1H),
7.16 (brs, 2H), 6.79 (d, J = 5.6 Hz, 1H), 6.23 (d, J = 6.0 Hz, 1H).
General Procedure for the Synthesis of Intermediates 15a and
15b. To a solution of 2-cyanoacetic acid 13 (15.0 g, 176.35 mmol) and
carbamate 14a or 14b (176.35 mmol) in the mixed solvents of toluene
(90 mL) and DMF (5.4 mL) was added POCl3 (8.22 mL, 88.18 mmol)
cooled with an ice bath. The reaction mixture was stirred at 80 °C for 3
h under argon and then slowly poured into ice-cold water (500 mL).
The precipitated solid was filtered and washed with saturated NH4Cl
and water to afford intermediates 15a and 15b, respectively.
Ethyl (2-Cyanoacetyl)carbamate (15a). Light yellow solid; yield
64%; mp 175−176 °C. 1H NMR (400 MHz, DMSO-d6) δ: 10.98 (brs,
1H), 4.15−4.10 (m, 2H), 4.09 (s, 2H), 1.21 (t, J = 6.8 Hz, 3H).
Methyl (2-Cyanoacetyl)carbamate (15b). White solid; yield 59%;
mp 175−176 °C. 1H NMR (400 MHz, DMSO-d6) δ: 11.04 (brs, 1H),
4.11 (s, 2H), 3.67 (s, 3H).
General Procedure for the Synthesis of Intermediates 16a and
16b. To a solution of 15a or 15b (102.3 mmol) in CH3OH (150 mL)
were added 2,5-dihydroxy-1,4-dithiane (7.77 g, 51.0 mmol) and Et3N
(15.6 mL, 112.3 mmol) in turn cooled with an ice bath. The reaction
mixture was stirred at 50 °C for 2.5 h under argon and then
concentrated. The residue was diluted with CH2Cl2 (100 mL) and
filtered. The obtained solid was washed with saturated NH4Cl solution
(100 mL) and water to afford intermediates 16a and 16b, respectively.
Ethyl (2-Aminothiophene-3-carbonyl)carbamate (16a). Light
yellow solid; yield 78%; mp 144−145 °C. 1H NMR (400 MHz,
DMSO-d6) δ: 10.02 (brs, 1H), 7.65 (brs, 2H), 7.25 (d, J = 6.0 Hz, 1H),
6.22 (d, J = 6.0 Hz, 1H), 4.16−4.10 (m, 2H), 1.23 (t, J = 7.6 Hz, 3H).
MS (ESI): m/z 215.05 (M + H)+.
Methyl (2-Aminothiophene-3-carbonyl)carbamate (16b). Light
Yellow solid; yield 59%; mp 152−153 °C. 1H NMR (400 MHz,
DMSO-d6) δ: 10.07 (brs, 1H), 7.65 (brs, 2H), 7.23 (d, J = 6.0 Hz, 1H),
6.23 (d, J = 6.0 Hz, 1H), 3.67 (s, 3H). MS (ESI):m/z 201.03 (M +H)+.
Procedure for the Synthesis of Intermediate 18. To a magnetically
stirred solution of 2-cyanoacetamide 17 (2.0 g, 23.79 mmol) in 1,2-
dichloroethane (50 mL) was added oxalyl chloride (6.0 mL, 71.36
mmol). The reaction mixture was heated to reflux for 4 h under an
argon atmosphere. The solvent was evaporated under reduced pressure.
To a solution of the residue in anhydrous acetonitrile (30 mL) was
added ethylamine (20.0 mL) in anhydrous acetonitrile (80 mL)
dropwise keeping the reaction under−10 °C. The reaction mixture was
stirred for additional 3 h at−10 °C and then concentrated. The residue
was washed with water, filtered, dried, and used in the next step without
further purification.
Procedure for the Synthesis of Intermediate 19. To a solution of
compound 18 (20.0 mg, 1.24 mmol) in CH3OH (20 mL) were added
2,5-dihydroxy-1,4-dithiane (98.0 mg, 0.65 mmol) and Et3N (0.27 mL,
1.94 mmol) cooled with an ice bath. The reaction mixture was stirred at
50 °C for 2.5 h under argon and then concentrated. The residue was
purified by silica gel column chromatography (CH2Cl2/MeOH = 100/
1) to give compound 19.
2-Amino-N-(ethylcarbamoyl)thiophene-3-carboxamide (19).
Yellow solid; yield 54%; mp 155−156 °C. 1H NMR (400 MHz,
DMSO-d6) δ: 9.68 (brs, 1H), 8.69−8.66 (m, 1H), 7.59 (brs, 2H), 7.36
(d, J = 6.0 Hz, 1H), 6.25 (d, J = 6.0 Hz, 1H), 3.23−3.20 (m, 2H), 1.09
(t, J = 6.8 Hz, 3H).
General Procedure for the Synthesis of Intermediates 21a−h. To
a solution of compounds 20a−h (1 equiv) and cyanoacetic acid 13 (3
equiv) in anhydrous DMFwere added EDCI (2 equiv) and DMAP (0.5
equiv). The reaction mixture was stirred under argon at room
temperature for 24 h. The reaction mixture was quenched with water
and extracted with ethyl acetate twice. The combined organic phase was
washed with brine, dried over anhydrous Na2SO4, filtered, and
evaporated in vacuo. The residue was purified by silica gel column
chromatography (CH2Cl2/MeOH = 100/1) to give compounds 21a−
h.
2-Cyano-N-(5-methylthiazol-2-yl)acetamide (21a). White solid;
yield 95%; mp 154−155 °C. 1H NMR (500 MHz, DMSO-d6) δ: 12.26
(brs, 1H), 7.15 (s, 1H), 4.00 (s, 2H), 2.35 (s, 3H).
2-Cyano-N-(4-methylpyrimidin-2-yl)acetamide (21b). White
solid; yield 82%; mp 133−134 °C. 1H NMR (400 MHz, DMSO-d6)
δ: 10.88 (brs, 1H), 8.51 (d, J = 4.8 Hz, 1H), 7.10 (d, J = 4.8 Hz, 1H),
4.16 (s, 2H), 2.42 (s, 3H).
2-Cyano-N-(4-(trifluoromethyl)pyrimidin-2-yl)acetamide (21c).
White solid; yield 50%; mp 186−188 °C. 1H NMR (400 MHz,
DMSO-d6) δ: 11.46 (brs, 1H), 9.05 (d, J = 4.8 Hz, 1H), 7.71 (d, J = 5.2
Hz, 1H), 4.15 (s, 2H).
2-Cyano-N-(5-methylpyrazin-2-yl)acetamide (21d). White solid;
yield 76%; mp 177−179 °C. 1H NMR (500 MHz, DMSO-d6) δ: 11.00
(brs, 1H), 9.12 (s, 1H), 8.29(s, 1H), 4.00 (s, 2H), 2.44 (s, 3H).
2-Cyano-N-(6-methylpyridin-2-yl)acetamide (21e). White solid;
yield 63%; mp 93−95 °C. 1H NMR (500 MHz, DMSO-d6) δ: 10.77
(brs, 1H), 7.81 (d, J = 6.0 Hz, 1H), 7.70 (t, J = 8.0 Hz, 1H), 7.01 (d, J =
7.5 Hz, 1H), 3.94 (s, 2H), 2.40 (s, 3H).
2-Cyano-N-(4-methylpyridin-2-yl)acetamide (21f). White solid;
yield 42%; mp 93−95 °C. 1H NMR (400 MHz, DMSO-d6) δ: 10.73
(brs, 1H), 8.18 (d, J = 5.2 Hz, 1H), 7.86 (brs, 1H), 6.99−6.97 (m, 1H),
3.96 (s, 2H), 2.32 (s, 3H).
2-Cyano-N-(4,6-dimethylpyrimidin-2-yl)acetamide (21g). White
solid; yield 38%; mp 157−158 °C. 1H NMR (500 MHz, DMSO-d6) δ:
10.78 (brs, 1H), 6.98 (s, 1H), 4.16 (s, 2H), 2.36 (s, 6H).
2-Cyano-N-(5-methylbenzo[d]thiazol-2-yl)acetamide (21h).
White solid; yield 13%; mp 174−176 °C. 1H NMR (400 MHz,
DMSO-d6) δ: 12.56 (brs, 1H), 7.75 (s, 1H), 7.61 (d, J = 8.0 Hz, 1H),
7.24−7.21 (m, 1H), 4.06 (s, 2H), 2.37 (s, 3H).
General Procedure for the Synthesis of Intermediates 22a−h. To
a solution of compound 21a−h (1 equiv) in methanol were added 2,5-
dihydroxy-1,4-dithiane (0.5 equiv) and Et3N (1.1 equiv). The reaction
mixture was stirred for 7 h under argon at 50 °C and then evaporated in
vacuo. The residue was purified by silica gel column chromatography
(CH2Cl2/MeOH = 100/1) to give compounds 22a−h.
2-Amino-N-(5-methylthiazol-2-yl)thiophene-3-carboxamide
(22a). Yellow solid; yield 66%; mp 178−180 °C. 1H NMR (500 MHz,
DMSO-d6) δ: 11.51 (brs, 1H), 7.57 (brs, 2H), 7.46 (d, J = 5.5 Hz, 1H),
7.14 (s, 1H), 6.30 (d, J = 6.0 Hz, 1H), 2.34 (s, 3H).
2-Amino-N-(4-methylpyrimidin-2-yl)thiophene-3-carboxamide
(22b). Yellow solid; yield 77%; mp 108−110 °C. 1H NMR (400 MHz,
CDCl3) δ: 8.49 (d, J = 5.2 Hz, 1H), 8.13 (brs, 1H), 6.89 (d, J = 5.6 Hz,
1H), 6.86 (d, J = 5.2 Hz, 1H), 6.44 (brs, 2H), 6.25 (d, J = 5.6 Hz, 1H),
2.49 (s, 3H).
2-Amino-N-(4-(trifluoromethyl)pyrimidin-2-yl)thiophene-3-car-
boxamide (22c). Yellow solid; yield 46%; mp 134−135 °C. 1H NMR
(400MHz, DMSO-d6) δ: 10.61 (brs, 1H), 9.01 (d, J = 4.8Hz, 1H), 7.64
(brs, 2H), 7.61 (d, J = 5.2 Hz, 1H), 7.35 (d, J = 6.0 Hz, 1H), 6.27 (d, J =
6.0 Hz, 1H).
2-Amino-N-(5-methylpyrazin-2-yl)thiophene-3-carboxamide
(22d). White solid; yield 31%; mp 178−179 °C. 1H NMR (400 MHz,
DMSO-d6) δ: 10.07 (s, 1H), 9.22 (s, 1H), 8.29 (s, 1H), 7.56 (brs, 2H),
7.47 (d, J = 6.0 Hz, 1H), 6.29 (d, J = 6.0 Hz, 1H), 2.45 (s, 3H).
2-Amino-N-(6-methylpyridin-2-yl)thiophene-3-carboxamide
(22e). Yellow solid; yield 70%; mp 140−141 °C. 1H NMR (500 MHz,
DMSO-d6) δ: 9.75 (brs, 1H), 7.93 (d, J = 8.0 Hz, 1H), 7.63 (t, J = 8.0
Hz, 1H), 7.50 (s, 1H), 7.49 (brs, 2H), 6.93 (d, J = 7.5Hz, 1H), 6.27 (d, J
= 5.5 Hz, 1H), 2.42 (s, 3H).
2-Amino-N-(4-methylpyridin-2-yl)thiophene-3-carboxamide
(22f). Brown oil; yield 40%. 1H NMR (500 MHz, DMSO-d6) δ: 9.79
(brs, 1H), 8.17 (s, 1H), 7.99 (s, 1H), 7.52 (brs, 2H), 7.48 (d, J = 4.5 Hz,
1H), 6.92 (s, 1H), 6.28 (d, J = 4.5 Hz, 1H), 2.31 (s, 3H).
2-Amino-N-(4,6-dimethylpyrimidin-2-yl)thiophene-3-carboxa-
mide (22g). White solid; yield 78%; mp 166−167 °C. 1H NMR (500
MHz, DMSO-d6) δ: 9.95 (brs, 1H), 7.51 (brs, 2H), 7.35 (d, J = 4.5 Hz,
1H), 6.93 (s, 1H), 6.25 (d, J = 4.0 Hz, 1H), 2.36 (s, 6H).
2-Amino-N-(5-methylbenzo[d]thiazol-2-yl)thiophene-3-carbox-
amide (22h).White solid; yield 74%; mp 217−218 °C. 1H NMR (400
MHz, DMSO-d6) δ: 11.88 (brs, 1H), 7.74 (s, 1H), 7.70 (brs, 2H), 7.60
(d, J = 8.4 Hz, 1H), 7.52 (d, J = 5.6 Hz, 1H), 7.24 (dd, J = 8.4, 1.2 Hz,
1H), 6.34 (d, J = 6.0 Hz, 1H), 2.41 (s, 3H).
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General Procedure for the Synthesis of Target Compounds 23a−
p. To a solution of benzoic acids 4a−p (1.2 equiv) and 2-
aminothiophene 16a (1 equiv) in DMF were added HATU (2 equiv)
and Et3N (3 equiv) in turn. The reaction mixture was stirred at room
temperature for 12 h, then quenched with water, and extracted with
CH2Cl2 thrice. The combined organic phase was washed with brine,
dried over anhydrous Na2SO4, filtered, and evaporated in vacuo. The
residue was purified by silica gel column chromatography (CH2Cl2/
MeOH = 100/1) to give target compounds 23a−p.
Ethyl (2-(4-(Propylcarbamoyl)benzamido)thiophene-3-
carbonyl)carbamate (23a). White solid; yield 35%; mp 219−220
°C. 1H NMR (400 MHz, DMSO-d6) δ: 12.64 (brs, 1H), 10.83 (brs,
1H), 8.67 (brs, 1H), 8.06−8.00 (m, 4H), 7.74 (d, J = 6.0 Hz, 1H), 7.10
(d, J = 6.0 Hz, 1H), 4.25−4.19 (m, 2H), 3.26−3.24 (m, 2H), 1.57−1.55
(m, 2H), 1.29 (t, J = 7.2 Hz, 3H), 0.91 (t, J = 7.2 Hz, 3H). 13C NMR
(100 MHz, DMSO-d6) δ: 165.3, 164.1, 162.6, 151.3, 149.0, 138.6,
133.9, 128.1, 127.3, 123.4, 117.0, 115.4, 61.4, 41.2, 22.4, 14.3, 11.6.
HRMS (ESI):m/z [M +H]+ calcd for C19H22N3O5S, 404.1275; found,
404.1267.
Ethyl (2-(4-(Ethyl(methyl)carbamoyl)benzamido)thiophene-3-
carbonyl)carbamate (23b). White solid; yield 57%; mp 161−162
°C. 1H NMR (400 MHz, DMSO-d6) δ: 12.66 (brs, 1H), 10.83 (brs,
1H), 8.01 (m, 2H), 7.75−7.64 (m, 3H), 7.11 (m, 1H), 4.23 (m, 2H),
3.20−3.10 (m, 2H), 2.98−2.88 (m, 3H), 1.29 (brs, 3H), 1.17−1.08 (m,
3H). 13C NMR (100 MHz, DMSO-d6) δ: 169.2 (168.6), 164.1, 162.4,
151.1, 149.1, 141.1, 132.2, 127.6 (127.5), 127.4 (127.1), 123.3, 116.8,
115.2, 61.3, 45.2 (41.5), 36.2 (31.6), 14.3, 13.3 (11.9). HRMS (ESI):
m/z [M + H]+ calcd for C19H22N3O5S, 404.1275; found, 404.1273.
Ethyl (2-(4-(Diethylcarbamoyl)benzamido)thiophene-3-
carbonyl)carbamate (23c). White solid; yield 10%; mp 178−179
°C. 1H NMR (500 MHz, DMSO-d6) δ: 12.65 (brs, 1H), 10.82 (brs,
1H), 8.00 (d, J = 7.5 Hz, 2H), 7.74 (d, J = 5.0 Hz, 1H), 7.61 (d, J = 7.5
Hz, 2H), 7.10 (d, J = 5.0 Hz, 1H), 4.22−4.21 (m, 2H), 3.46 (brs, 2H),
3.17 (brs, 2H), 1.29 (t, J = 7.0 Hz, 3H), 1.17 (brs, 3H), 1.06 (brs, 3H).
13C NMR (100 MHz, DMSO-d6) δ: 169.0, 164.2, 162.5, 151.2, 149.2,
141.5, 132.1, 127.6, 127.0, 123.4, 116.9, 115.3, 61.4, 42.9, 38.8, 14.3,
14.1, 12.9. HRMS (ESI): m/z [M + H]+ calcd for C20H24N3O5S,
418.1431; found, 418.1411.
Ethyl (2-(4-(((3S,5S,7S)-Adamantan-1-yl)carbamoyl)-
benzamido)thiophene-3-carbonyl)carbamate (23d). White solid;
yield 4%; mp 157−158 °C. 1H NMR (400 MHz, DMSO-d6) δ: 12.65
(brs, 1H), 10.82 (brs, 1H), 8.00−7.95 (m, 4H), 7.84 (brs, 1H), 7.74 (d,
J = 6.0 Hz, 1H), 7.10 (d, J = 6.0 Hz, 1H), 4.25−4.19 (m, 2H), 2.09−
2.07 (m, 10H), 1.67 (brs, 5H), 1.29 (t, J = 7.2 Hz, 3H). 13C NMR (100
MHz, DMSO-d6) δ: 165.3, 164.2, 162.6, 151.3, 149.1, 139.9, 133.6,
128.3, 127.1, 123.4, 116.9, 115.3, 61.4, 51.9, 40.9, 36.1, 29.0, 14.3.
HRMS (ESI):m/z [M +H]+ calcd for C26H30N3O5S, 496.1901; found,
496.1881.
Ethyl (2-(4-(Cyclohexylcarbamoyl)benzamido)thiophene-3-
carbonyl)carbamate (23e). White solid; yield 11%; mp > 250 °C.
1H NMR (400 MHz, DMSO-d6) δ: 12.64 (brs, 1H), 10.82 (brs, 1H),
8.42 (d, J = 8.0 Hz, 1H), 8.05−7.99 (m, 4H), 7.74 (d, J = 6.0 Hz, 1H),
7.10 (d, J = 6.0 Hz, 1H), 4.25−4.19 (m, 2H), 3.79−3.77 (m, 1H),
1.84−1.72 (m, 4H), 1.64−1.59 (m, 1H), 1.35−1.27 (m, 7H), 1.24−
1.22 (m, 1H). 13C NMR (100 MHz, DMSO-d6) δ: 164.6, 164.1, 162.6,
151.3, 149.1, 138.8, 133.8, 128.2, 127.2, 123.4, 117.0, 115.4, 61.4, 48.6,
32.4, 25.3, 25.0, 14.3. HRMS (ESI): m/z [M + H]+ calcd for
C22H26N3O5S, 444.1588; found, 444.1597.
Ethyl (2-(4-((4,4-Dimethylcyclohexyl)carbamoyl)benzamido)-
thiophene-3-carbonyl)carbamate (23f). White solid; yield 17%; mp
> 250 °C. 1H NMR (400 MHz, DMSO-d6) δ: 12.64 (brs, 1H), 10.82
(brs, 1H), 8.41 (d, J = 8.0 Hz, 1H), 8.05−8.00 (m, 4H), 7.74 (d, J = 6.0
Hz, 1H), 7.10 (d, J = 6.0 Hz, 1H), 4.24−4.19 (m, 2H), 3.75−3.72 (m,
1H), 1.65−1.64 (m, 2H), 1.59−1.50 (m, 2H), 1.42−1.39 (m, 2H),
1.30−1.27 (m, 5H), 0.94 (s, 3H), 0.92 (s, 3H). 13C NMR (100 MHz,
DMSO-d6) δ: 164.6, 164.2, 162.6, 151.3, 149.1, 138.8, 133.9, 128.2,
127.3, 123.4, 117.0, 115.4, 61.4, 48.7, 37.7, 32.1, 29.4, 28.0, 24.4, 14.3.
HRMS (ESI):m/z [M +H]+ calcd for C24H30N3O5S, 472.1901; found,
472.1909.
Ethyl (2-(4-(Phenylcarbamoyl)benzamido)thiophene-3-
carbonyl)carbamate (23g). White solid; yield 39%; mp > 250 °C.
1H NMR (400 MHz, DMSO-d6) δ: 12.69 (brs, 1H), 10.84 (brs, 1H),
10.46 (brs, 1H), 8.16 (d, J = 8,4 Hz, 2H), 8.08 (d, J = 8,4 Hz, 2H), 7.79
(d, J = 8,0 Hz, 2H), 7.75 (d, J = 6,0 Hz, 1H), 7.40−7.36 (m, 2H), 7.15−
7.11 (m, 2H), 4.25−4.20 (m, 2H), 1.29 (t, J = 7.6 Hz, 3H). 13C NMR
(100 MHz, DMSO-d6) δ: 164.8, 164.2, 162.5, 151.3, 149.1, 139.0,
138.9, 134.3, 128.7, 128.6, 127.4, 124.0, 123.4, 120.5, 116.9, 115.4, 61.4,
14.3. HRMS (ESI): m/z [M + H]+ calcd for C22H20N3O5S, 438.1118;
found, 438.1119.
Ethyl (2-(4-(Azetidine-1-carbonyl)benzamido)thiophene-3-
carbonyl)carbamate (23h). White solid; yield 40%; mp 182−183
°C. 1H NMR (400 MHz, DMSO-d6) δ: 12.66 (brs, 1H), 10.82 (brs,
1H), 8.01 (d, J = 8.0 Hz, 2H), 7.85 (d, J = 8.0 Hz, 2H), 7.74 (d, J = 6.0
Hz, 1H), 7.10 (d, J = 6.0 Hz, 1H), 4.33 (t, J = 7.6 Hz, 2H). 4.24−4.19
(m, 2H), 4.08 (t, J = 7.6 Hz, 2H), 2.32−2.24 (m, 2H), 1.29 (t, J = 7.6
Hz, 3H). 13C NMR (100 MHz, DMSO-d6) δ: 167.8, 164.2, 162.4,
151.2, 149.1, 137.2, 133.6, 128.6, 127.4, 123.4, 116.9, 115.3, 61.4, 53.0,
48.7, 15.6, 14.3. HRMS (ESI): m/z [M + H]+ calcd for C19H20N3O5S,
402.1118; found, 402.1097.
Ethyl (2-(4-(Pyrrolidine-1-carbonyl)benzamido)thiophene-3-
carbonyl)carbamate (23i). White solid; yield 8%; mp 172−173 °C.
1H NMR (400 MHz, DMSO-d6) δ: 12.66 (brs, 1H), 10.83 (brs, 1H),
8.00 (d, J = 8.0 Hz, 2H), 7.77−7.73 (m, 3H), 7.10 (d, J = 5.6 Hz, 1H),
4.24−4.19 (m, 2H), 3.50 (t, J = 6.4 Hz, 2H), 3.38 (t, J = 6.4 Hz, 2H),
1.90−1.81 (m, 4H), 1.29 (t, J = 7.2 Hz, 3H). 13C NMR (100 MHz,
DMSO-d6) δ: 167.2, 164.2, 162.5, 151.2, 149.1, 141.3, 132.7, 127.9,
127.3, 123.4, 116.9, 115.3, 61.4, 48.9, 46.0, 26.0, 24.0, 14.3. HRMS
(ESI): m/z [M + H]+ calcd for C20H22N3O5S, 416.1275; found,
416.1256.
Ethyl (2-(4-(Piperidine-1-carbonyl)benzamido)thiophene-3-
carbonyl)carbamate (23j). White solid; yield 33%; mp 177−178 °C.
1H NMR (400 MHz, DMSO-d6) δ: 12.64 (brs, 1H), 10.81 (brs, 1H),
8.00 (d, J = 8.0 Hz, 2H), 7.74 (d, J = 6.0 Hz, 1H), 7.62 (d, J = 8.0 Hz,
2H), 7.10 (d, J = 6.0 Hz, 1H), 4.24−4.19 (m, 2H), 3.61 (brs, 2H), 3.25
(brs, 2H), 1.62 (brs, 4H), 1.47 (brs, 2H), 1.29 (t, J = 6.8 Hz, 3H). 13C
NMR (100 MHz, DMSO-d6) δ: 167.8, 164.2, 162.5, 151.2, 149.1,
140.8, 132.4, 127.6, 127.5, 123.4, 116.9, 115.3, 61.4, 48.0, 42.4, 26.0,
25.3, 24.1, 14.3. HRMS (ESI): m/z [M + H]+ calcd for C21H24N3O5S,
430.1431; found, 430.1435.
Ethyl (2-(4-(Azepane-1-carbonyl)benzamido)thiophene-3-
carbonyl)carbamate (23k). White solid; yield 34%; mp 148−149
°C. 1H NMR (400 MHz, DMSO-d6) δ: 12.65 (brs, 1H), 10.82 (brs,
1H), 8.00 (d, J = 8.2 Hz, 2H), 7.74 (d, J = 5.6 Hz, 1H), 7.61 (d, J = 8.2
Hz, 2H), 7.10 (d, J = 5.6 Hz, 1H), 4.24−4.19 (m, 2H), 3.58 (brs, 2H),
3.29 (brs, 2H), 1.73 (brs, 2H), 1.62−1.48 (m, 6H), 1.28 (t, J = 7.0 Hz,
3H). 13C NMR (100 MHz, DMSO-d6) δ: 169.2, 164.1, 162.5, 151.2,
149.1, 141.5, 132.0, 127.4, 127.1, 123.3, 116.8, 115.2, 61.3, 49.0, 45.4,
28.7, 27.1, 26.8, 25.8, 14.2. HRMS (ESI): m/z [M + H]+ calcd for
C22H26N3O5S, 444.1588; found, 444.1563.
Ethyl (2-(4-(4-Methylpiperidine-1-carbonyl)benzamido)-
thiophene-3-carbonyl)carbamate (23l). White solid; yield 47%; mp
79−81 °C. 1H NMR (400 MHz, DMSO-d6) δ: 12.64 (brs, 1H), 10.82
(brs, 1H), 8.00 (d, J = 8.4 Hz, 2H), 7.74 (d, J = 6.0 Hz, 1H), 7.62 (d, J =
8.4 Hz, 2H), 7.10 (d, J = 6.0 Hz, 1H), 4.24−4.19 (m, 2H), 3.13−3.07
(m, 4H), 1.29 (t, J = 6.0 Hz, 3H), 1.19−1.15 (m, 5H), 0.93 (d, J = 6.8
Hz, 3H). 13C NMR (100 MHz, DMSO-d6) δ: 167.7, 164.1, 162.5,
151.2, 149.1, 140.7, 132.3, 127.5, 127.4, 123.3, 116.8, 115.2, 61.3, 47.2,
41.6, 34.0, 33.4, 30.4, 21.6, 14.2. HRMS (ESI):m/z [M + H]+ calcd for
C22H26N3O5S, 444.1588; found, 444.1577.
Ethyl (2-(4-(4-Methoxypiperidine-1-carbonyl)benzamido)-
thiophene-3-carbonyl)carbamate (23m). White solid; yield 15%;
mp 160−161 °C. 1H NMR (400 MHz, DMSO-d6) δ: 12.64 (brs, 1H),
10.82 (brs, 1H), 8.00 (d, J = 8.0 Hz, 2H), 7.74 (d, J = 6.0 Hz, 1H), 7.64
(d, J = 8.0 Hz, 2H), 7.10 (d, J = 6.0 Hz, 1H), 4.24−4.19 (m, 2H), 3.93
(brs, 1H), 3.45−3.32 (m, 3H), 3.26 (s, 3H), 3.15 (brs, 1H), 1.90−1.80
(m, 2H), 1.44 (brs, 2H), 1.29 (t, J = 7.2 Hz, 3H). 13C NMR (100 MHz,
DMSO-d6) δ: 167.9, 164.2, 162.5, 151.2, 149.1, 140.5, 132.5, 127.6,
123.4, 116.9, 115.3, 74.9, 61.4, 55.1, 44.5, 30.8, 30.1, 14.3. HRMS
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(ESI): m/z [M + H]+ calcd for C22H26N3O6S, 460.1537; found,
460.1533.
Ethyl (2-(4-(4,4-Difluoropiperidine-1-carbonyl)benzamido)-
thiophene-3-carbonyl)carbamate (23n). White solid; yield 57%;
mp 177−178 °C. 1H NMR (400 MHz, DMSO-d6) δ: 12.65 (brs, 1H),
10.82 (brs, 1H), 8.01 (d, J = 8.4 Hz, 2H), 7.74−7.70 (m, 3H), 7.10 (d, J
= 5.6 Hz, 1H), 4.24−4.19 (m, 2H), 3.87−3.76 (m, 2H), 3.48−3.40 (m,
2H), 2.06 (brs, 4H), 1.29 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz,
DMSO-d6) δ: 168.2, 164.2, 162.5, 151.2, 149.1, 139.9, 132.8, 127.7,
127.6, 123.4, 122.8 (J = 240 Hz), 116.9, 115.3, 61.4, 44.0, 38.5, 33.7,
14.3. HRMS (ESI): m/z [M + H]+ calcd for C21H22F2N3O5S,
466.1243; found, 466.1220.
Ethyl (2-(4-(Morpholine-4-carbonyl)benzamido)thiophene-3-
carbonyl)carbamate (23o). White solid; yield 79%; mp 159−160
°C. 1H NMR (400 MHz, DMSO-d6) δ: 12.65 (brs, 1H), 10.82 (brs,
1H), 8.01 (d, J = 7.6 Hz, 2H), 7.74 (d, J = 5.6 Hz, 1H), 7.67 (d, J = 7.6
Hz, 2H), 7.10 (d, J = 5.6 Hz, 1H), 4.22−4.21 (m, 2H), 3.66−3.57 (m,
6H), 3.33 (brs, 2H), 1.29 (t, J = 6.8 Hz, 3H). 13C NMR (100 MHz,
DMSO-d6) δ: 168.0, 164.1, 162.4, 151.2, 149.0, 139.7, 132.6, 127.8,
127.5, 123.3, 116.8, 115.2, 66.0, 61.3, 47.6, 42.0, 14.2. HRMS (ESI):m/
z [M + H]+ calcd for C20H22N3O6S, 432.1224; found, 432.1207.
Ethyl (2-(4-(Thiomorpholine-4-carbonyl)benzamido)thiophene-
3-carbonyl)carbamate (23p). White solid; yield 17%; mp 178−179
°C. 1H NMR (400 MHz, DMSO-d6) δ: 12.64 (brs, 1H), 10.82 (brs,
1H), 8.01 (d, J = 8.4 Hz, 2H), 7.74 (d, J = 6.0 Hz, 1H), 7.66 (d, J = 8.4
Hz, 2H), 7.10 (d, J = 6.0 Hz, 1H), 4.24−4.19 (m, 2H), 3.90−3.89 (m,
2H), 3.52 (brs, 2H), 2.70−2.50 (m, 4H), 1.29 (t, J = 7.6 Hz, 3H). 13C
NMR (100 MHz, DMSO-d6) δ: 168.4, 164.2, 162.5, 151.2, 149.1,
140.3, 132.5, 127.6, 127.5, 123.4, 116.9, 115.3, 61.4, 49.7, 44.0, 27.0,
26.7, 14.3. HRMS (ESI): m/z [M + H]+ calcd for C20H22N3O5S2,
448.0995; found, 448.0971.
General Procedure for the Synthesis of Target Compounds 24a,
24c, 24d, 24f, and 24h−l. The target compounds were prepared from
16a and corresponding aryl carboxylic acids 7 in the same manner as
described for 23a−p.
General Procedure for the Synthesis of Target Compounds 24b,
24e, and 24g. To a magnetically stirred solution of the benzoic acids
7b, 7e or 7g (1 equiv) in CH2Cl2 were added thionyl chloride (2 equiv)
and a drop of DMF. The reaction mixture was heated to reflux for 3 h
under an argon atmosphere. The solvent was evaporated under reduced
pressure. The residue was dissolved in anhydrous THF. To a solution of
2-aminothiophene 16a (0.7 equiv), DMAP (0.07 equiv), and Et3N (3.5
equiv) in anhydrous THF was slowly added the above THF solution
cooled with an ice bath. The reaction mixture was stirred for additional
3 h at room temperature and then concentrated. The residue was
purified by silica gel column chromatography (CH2Cl2/MeOH = 100/
1) to give target compounds 24b, 24e, and 24g, respectively.
Ethyl (2-(3-(Piperidine-1-carbonyl)benzamido)thiophene-3-
carbonyl)carbamate (24a). White solid; yield 18%; mp 175−176
°C. 1H NMR (500 MHz, DMSO-d6) δ: 12.63 (brs, 1H), 10.81 (brs,
1H), 8.00 (brs, 1H), 7.89 (brs, 1H), 7.79−7.72 (m, 3H), 7.10 (s, 1H),
4.22−4.21 (m, 2H), 3.62 (brs, 2H), 3.30 (brs, 2H), 1.62 (brs, 4H), 1.50
(brs, 2H), 1.28 (brs, 3H). 13C NMR (100 MHz, DMSO-d6) δ: 167.8,
164.1, 162.5, 151.3, 149.1, 137.4, 132.2, 131.0, 129.6, 128.0, 125.6,
123.4, 116.9, 115.3, 61.4, 48.2, 42.5, 26.0, 25.3, 24.1, 14.3. HRMS
(ESI): m/z [M + H]+ calcd for C21H24N3O5S, 430.1431; found,
430.1434.
Ethyl (2-(2-Fluoro-4-(piperidine-1-carbonyl)benzamido)-
thiophene-3-carbonyl)carbamate (24b). White solid; yield 38%;
mp 163−164 °C. 1H NMR (400 MHz, DMSO-d6) δ: 12.71 (d, J = 9.6
Hz, 1H), 10.77 (brs, 1H), 8.10 (t, J = 7.6 Hz, 1H), 7.73 (d, J = 6.0 Hz,
1H), 7.53 (d, J = 7.6 Hz, 1H), 7.41 (dd, J1 = 8.0 Hz, J2 = 1.2 Hz, 1H),
7.12 (d, J = 6.0 Hz, 1H), 4.24−4.18 (m, 2H), 3.60 (brs, 2H), 3.25 (brs,
2H), 1.61−1.60 (m, 4H), 1.47 (brs, 2H), 1.28 (t, J = 7.6 Hz, 3H). 13C
NMR (100 MHz, DMSO-d6) δ: 166.4, 163.6, 159.8 (q, J = 250 Hz),
159.2 (q, J = 2 Hz), 151.3, 148.3, 143.0 (q, J = 8 Hz), 139.2, 132.1,
123.5, 119.8 (J = 11 Hz), 117.3, 115.7, 115.1 (q, J = 25 Hz), 61.4, 48.0,
42.4, 25.9, 25.2, 24.0, 14.3. HRMS (ESI): m/z [M + H]+ calcd for
C21H23FN3O5S, 448.1337; found, 448.1342.
Ethyl (2-(2-Chloro-4-(piperidine-1-carbonyl)benzamido)-
thiophene-3-carbonyl)carbamate (24c). White solid; yield 16%; mp
59−60 °C. 1H NMR (400 MHz, DMSO-d6) δ: 12.12 (brs, 1H), 10.74
(brs, 1H), 7.79 (d, J = 7.6 Hz, 1H), 7.65 (d, J = 6.0 Hz, 1H), 7.58 (d, J =
1.2 Hz, 1H), 7.46 (dd, J1 = 7.6 Hz, J2 = 1.2 Hz, 1H), 7.09 (d, J = 6.0 Hz,
1H), 4.17−4.11 (m, 2H), 3.55 (brs, 2H), 3.23 (brs, 2H), 1.58−1.52 (m,
4H), 1.44 (br, 2H), 1.22 (t, J = 7.2 Hz, 3H). 13C NMR (100 MHz,
DMSO-d6) δ: 166.4, 163.5, 162.5, 151.3, 147.8, 140.8, 133.8, 130.7,
130.3, 128.4, 125.8, 123.5, 117.2, 116.0, 61.3, 48.1, 42.4, 25.9, 25.2,
24.0, 14.3. HRMS (ESI): m/z [M + H]+ calcd for C21H23ClN3O5S,
464.1042; found, 464.0981.
Ethyl (2-(2-Bromo-4-(piperidine-1-carbonyl)benzamido)-
thiophene-3-carbonyl)carbamate (24d). White solid; yield 9%; mp
144−145 °C. 1H NMR (400 MHz, DMSO-d6) δ: 12.04 (brs, 1H),
10.79 (brs, 1H), 7.78−7.76 (m, 2H), 7.69 (d, J = 6.0 Hz, 1H), 7.54 (d, J
= 8.0 Hz, 1H), 7.14 (d, J = 6.0 Hz, 1H), 4.21−4.16 (m, 2H), 3.59 (brs,
2H), 3.28 (brs, 2H), 1.61 (brs, 4H), 1.49 (brs, 2H), 1.26 (t, J = 7.2 Hz,
3H). 13C NMR (100 MHz, DMSO-d6) δ: 166.4, 163.6, 151.3, 147.8,
140.6, 136.3, 131.4, 129.8, 126.2, 123.5, 119.4, 117.2, 116.0, 61.4, 48.1,
42.4, 25.9, 25.2, 24.0, 14.3. HRMS (ESI): m/z [M + H]+ calcd for
C21H23BrN3O5S, 508.0536; found, 508.0471.
Ethyl (2-(2-Nitro-4-(piperidine-1-carbonyl)benzamido)-
thiophene-3-carbonyl)carbamate (24e). White solid; yield 27%;
mp 113−114 °C. 1H NMR (400 MHz, DMSO-d6) δ: 12.05 (brs, 1H),
10.79 (brs, 1H), 8.15 (m, 1H), 7.91−7.90 (m, 2H), 7.65 (d, J = 6.0 Hz,
1H), 7.15 (d, J = 6.0 Hz, 1H), 4.20−4.15 (m, 2H), 3.62 (brs, 2H), 3.32
(brs, 2H), 1.61 (brs, 4H), 1.49 (brs, 2H), 1.26 (t, J = 7.2 Hz, 3H). 13C
NMR (100 MHz, DMSO-d6) δ: 165.9, 163.2, 162.5, 151.3, 147.4,
146.9, 139.9, 132.0, 130.6, 129.4, 123.6, 122.9, 117.3, 116.6, 61.3, 48.1,
42.6, 25.9, 25.2, 24.0, 14.3. HRMS (ESI): m/z [M + H]+ calcd for
C21H23N4O7S, 475.1282; found, 475.1288.
Ethyl (2-(3-Fluoro-4-(piperidine-1-carbonyl)benzamido)-
thiophene-3-carbonyl)carbamate (24f). Off white solid; yield 48%;
mp 186−187 °C. 1H NMR (400 MHz, DMSO-d6) δ: 12.59 (brs, 1H),
10.84 (brs, 1H), 7.83−7.79 (m, 2H), 7.73 (d, J = 6.0 Hz, 1H), 7.69−
7.65 (m, 1H), 7.12 (d, J = 6.0 Hz, 1H), 4.22−4.19 (m, 2H), 3.65−3.62
(m, 2H), 3.21−3.18 (m, 2H), 1.63−1.57 (m, 4H), 1.46 (brs, 2H), 1.28
(t, J = 7.2 Hz, 3H). 13C NMR (100 MHz, DMSO-d6) δ: 164.0, 162.8,
161.5, 157.6 (q, J = 246 Hz), 151.2, 148.7, 134.8 (q, J = 13 Hz), 129.7,
128.7 (J = 9 Hz), 123.7, 123.5, 117.1, 115.7, 115.1 (q, J = 24 Hz), 61.4,
47.6, 42.1, 26.1, 25.3, 23.9, 14.3. HRMS (ESI):m/z [M + H]+ calcd for
C21H23FN3O5S, 448.1337; found, 448.1338.
Ethyl (2-(3-Methyl-4-(piperidine-1-carbonyl)benzamido)-
thiophene-3-carbonyl)carbamate (24g). White solid; yield 9%; mp
103−104 °C. 1H NMR (150 MHz, DMSO-d6) δ: 12.58 (brs, 1H),
10.80 (brs, 1H), 7.84 (s, 1H), 7.79 (d, J = 7.8 Hz, 1H), 7.73 (d, J = 6.0
Hz, 1H), 7.42 (d, J = 7.2 Hz, 1H), 7.09 (d, J = 6.0 Hz, 1H), 4.23−4.21
(m, 2H), 3.68−3.59 (m, 2H), 3.10−3.09 (m, 2H), 2.32 (s, 3H), 1.60−
1.56 (m, 4H), 1.43−1.39 (m, 2H), 1.28 (t, J = 7.2 Hz, 3H). 13C NMR
(150 MHz, DMSO-d6) δ: 167.3, 164.1, 162.7, 151.2, 149.2, 141.2,
134.9, 131.9, 129.2, 126.5, 124.8, 123.4, 116.8, 115.2, 61.4, 47.2, 41.7,
26.1, 25.4, 24.0, 18.7, 14.3. HRMS (ESI): m/z [M + H]+ calcd for
C22H26N3O5S, 444.1588; found, 444.1575.
Ethyl (2-(6-(Piperidine-1-carbonyl)-2-naphthamido)thiophene-
3-carbonyl)carbamate (24h). White solid; yield 22%; mp 177−178
°C. 1H NMR (500 MHz, DMSO-d6) δ: 12.75 (brs, 1H), 10.86 (brs,
1H), 8,63 (s, 1H), 8.24 (d, J = 8.5 Hz, 2H), 8.08 (s, 1H), 8.02 (d, J = 8.5
Hz, 1H), 7.75 (d, J = 5.5 Hz, 1H), 7.62 (d, J = 8.5 Hz, 1H), 7.12 (d, J =
5.5 Hz, 1H), 4.25−4.21 (m, 2H), 3.65 (brs, 2H), 3.35 (brs, 2H), 1.63
(brs, 4H), 1.49 (brs, 2H), 1.30 (t, J = 9.0Hz, 3H). 13CNMR (100MHz,
DMSO-d6) δ: 168.4, 164.2, 163.1, 151.3, 149.3, 136.5, 134.3, 132.2,
130.0, 129.7, 129.6, 128.3, 125.9, 125.6, 123.8, 123.4, 116.9, 115.3, 61.4,
48.2, 42.5, 26.1, 25.4, 24.1, 14.3. HRMS (ESI):m/z [M + H]+ calcd for
C25H26N3O5S, 480.1588; found, 480.1594.
Ethyl (2-(4′-(Piperidine-1-carbonyl)-[1,1′-biphenyl]-4-
carboxamido)thiophene-3-carbonyl)carbamate (24i). Light yellow
solid; yield 83%; mp 187−188 °C. 1H NMR (400 MHz, DMSO-d6) δ:
12.70 (brs, 1H), 10.83 (brs, 1H), 8.06 (d, J = 8.0 Hz, 2H), 7.99 (d, J =
8.0 Hz, 2H), 7.84 (d, J = 8.0 Hz, 2H), 7.74 (d, J = 6.0 Hz, 1H), 7.51 (d, J
= 8.0 Hz, 2H), 7.10 (d, J = 6.0 Hz, 1H), 4.25−4.20 (m, 2H), 3.60 (brs,
2H), 3.32 (brs, 2H), 1.63 (brs, 2H), 1.52 (brs, 4H), 1.29 (t, J = 7.2 Hz,
3H). 13C NMR (100 MHz, DMSO-d6) δ: 168.5, 164.2, 162.7, 151.3,
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149.3, 143.7, 139.5, 136.5, 130.9, 128.0, 127.7, 127.6, 127.1, 123.4,
116.8, 115.1, 61.4, 48.1, 42.4, 26.1, 25.3, 24.1, 14.3. HRMS (ESI): m/z
[M + H]+ calcd for C27H28N3O5S, 506.1477; found, 506.1756.
Ethyl (2-(5-(Piperidine-1-carbonyl)thiophene-2-carboxamido)-
thiophene-3-carbonyl)carbamate (24j). Light yellow solid; yield
21%; mp 175−176 °C. 1H NMR (400 MHz, DMSO-d6) δ: 12.50 (brs,
1H), 10.82 (brs, 1H), 7.75−7.74 (m, 1H), 7.71 (d, J = 6.0 Hz, 1H),
7.49−7.48 (m, 1H), 7.10 (d, J = 6.0 Hz, 1H), 4.24−4.20 (m, 2H), 3.59
(brs, 4H), 1.64 (brs, 2H), 1.56 (brs, 4H), 1.29 (t, J = 7.2 Hz, 3H). 13C
NMR (100 MHz, DMSO-d6) δ: 164.0, 161.0, 157.5, 151.2, 148.5,
143.6, 137.9, 129.5, 129.4, 123.4, 117.1, 115.4, 61.4, 47.8, 43.3, 25.8,
24.0, 14.3. HRMS (ESI): m/z [M + H]+ calcd for C19H22N3O5S2,
436.0995; found, 436.0985.
Ethyl (2-(5-(Piperidine-1-carbonyl)furan-3-carboxamido)-
thiophene-3-carbonyl)carbamate (24k). White solid; yield 18%;
mp 157−158 °C. 1H NMR (400 MHz, DMSO-d6) δ: 12.12 (brs, 1H),
10.78 (brs, 1H), 8.60 (s, 1H), 7.68 (d, J = 6.0 Hz, 1H), 7.22 (s, 1H),
7.07 (d, J = 6.0 Hz, 1H), 4.24−4.18 (m, 2H), 3.62 (brs, 4H), 1.65−1.64
(m, 2H), 1.57−1.56 (m, 4H), 1.28 (t, J = 6.8 Hz, 3H). 13C NMR (150
MHz, DMSO-d6) δ: 163.8, 158.1, 157.5, 151.3, 148.8, 148.4, 147.5,
123.4, 121.8, 116.9, 115.3, 112.2, 61.4, 47.3, 43.2, 26.3, 25.4, 24.1, 14.3.
HRMS (ESI):m/z [M +H]+ calcd for C19H22N3O6S, 420.1224; found,
420.1217.
Ethyl (2-(4-(Piperidine-1-carbonyl)-1H-pyrrole-2-carboxamido)-
thiophene-3-carbonyl)carbamate (24l). White solid; yield 8%; mp
183−184 °C. 1H NMR (400 MHz, DMSO-d6) δ: 12.42 (brs, 1H),
12.15 (brs, 1H), 10.74 (brs, 1H), 7.66 (d, J = 6.0 Hz, 1H), 7.01 (d, J =
6.0 Hz, 1H), 6.83−6.81 (m, 1H), 6.51−6.50 (m, 1H), 4.24−4.18 (m,
2H), 3.59−3.56 (m, 4H), 1.64−1.63 (m, 2H), 1.54−1.50 (m, 4H), 1.28
(t, J = 7.2 Hz, 3H). 13C NMR (150 MHz, DMSO-d6) δ: 163.9, 160.8,
156.5, 151.3, 149.2, 130.8, 125.6, 123.2, 116.3, 114.5, 112.0, 111.6, 61.3,
47.6, 43.1, 25.8, 24.2, 14.3. HRMS (ESI): m/z [M + H]+ calcd for
C19H23N4O5S, 419.1384; found, 419.1370.
Procedure for the Synthesis of Target Compound 25a. Target
compound 25a was prepared from 4j (1.85 g, 7.93 mmol) and 16b
(1.32 g, 6.6 mmol) in the same manner as described for 23a−p.
Methyl (2-(4-(Piperidine-1-carbonyl)benzamido)thiophene-3-
carbonyl)carbamate (25a). White solid; yield 13%; mp: 151−152
°C. 1H NMR (400 MHz, DMSO-d6) δ: 12.63 (brs, 1H), 10.85 (brs,
1H), 8.00 (d, J = 8.0 Hz, 2H), 7.73 (d, J = 6.0 Hz, 1H), 7.62 (d, J = 8.0
Hz, 2H), 7.11 (d, J = 6.0 Hz, 1H), 3.76 (s, 3H), 3.61 (brs, 2H), 3.25
(brs, 2H), 1.62 (brs, 4H), 1.47 (brs, 2H). 13C NMR (100 MHz,
DMSO-d6) δ: 167.8, 164.0, 162.5, 151.8, 149.2, 140.8, 132.3, 127.6,
127.5, 123.3, 116.9, 115.2, 52.5, 48.0, 42.4, 26.0, 25.3, 24.1. HRMS
(ESI): m/z [M + H]+ calcd for C20H22N3O5S, 416.1275; found,
416.1261.
Procedure for the Synthesis of Target Compound 25b. Target
compound 25b was prepared from 7f (326.7 mg, 1.3 mmol) and 16b
(200.0 mg, 1.0 mmol) in the same manner as described for 23a−p.
Methyl (2-(3-Fluoro-4-(piperidine-1-carbonyl)benzamido)-
thiophene-3-carbonyl)carbamate (25b). White solid; yield 51%;
mp 159−160 °C. 1H NMR (400 MHz, DMSO-d6) δ: 12.58 (brs, 1H),
10.86 (brs, 1H), 7.82−7.78 (m, 2H), 7.72 (d, J = 6.0 Hz, 1H), 7.69−
7.65 (m, 1H), 7.12 (d, J = 6.0 Hz, 1H), 3.75 (s, 3H), 3.63 (brs, 2H),
3.20 (brs, 2H), 1.61−1.57 (m, 4H), 1.46 (brs, 2H). 13C NMR (100
MHz, DMSO-d6) δ: 163.8, 162.7, 161.4, 157.5 (J = 246 Hz), 151.7,
148.7, 134.6 (J = 7 Hz), 129.6, 128.7 (J = 19 Hz), 123.6, 123.3, 117.1,
115.5, 115.0 (J = 24 Hz), 52.4, 47.5, 42.1, 26.0, 25.2, 23.9. HRMS
(ESI): m/z [M + H]+ calcd for C20H21FN3O5S, 434.1181; found,
434.1177.
Procedure for the Synthesis of Target Compound 25c. Target
compound 25c was prepared from 4j (131 mg, 0.56 mmol) and 19 (80
mg, 0.38 mmol) in the same manner as described for 23a−p.
N-(Ethylcarbamoyl)-2-(4-(piperidine-1-carbonyl)benzamido)-
thiophene-3-carboxamide (25c). Yellow solid; yield 31%; mp 223−
224 °C. 1HNMR (400MHz, DMSO-d6) δ: 12.49 (brs, 1H), 10.43 (brs,
1H), 8.55−8.52 (m, 1H), 8.00 (d, J = 8.0 Hz, 2H), 7.82 (d, J = 6.0 Hz,
1H), 7.60 (d, J = 8.0 Hz, 2H), 7.11 (d, J = 6.0 Hz, 1H), 3.61 (brs, 2H),
3.30−3.25 (m, 4H), 1.62−1.58 (m, 4H), 1.47 (brs, 2H), 1.14 (t, J = 7.2
Hz, 3H). 13C NMR (100 MHz, DMSO-d6) δ: 167.8, 166.0, 162.6,
153.2, 148.8, 140.8, 132.5, 127.6, 127.4, 123.2, 117.2, 114.7, 48.0, 42.4,
34.3, 26.0, 25.3, 24.1, 15.1. HRMS (ESI): m/z [M + H]+ calcd for
C21H25N4O4S, 429.1591; found, 429.1596.
Procedure for the Synthesis of Target Compound 25d. To a
solution of 25a (50 mg, 0.12 mmol) in 30 mL of CH3OH was added 1
mol/L LiOH aqueous solution (0.6 mL). The reaction mixture was
heated to reflux for 2 h and then concentrated. The residue was diluted
with CH2Cl2 (30 mL), washed with water (30 mL) and brine (30 mL),
dried over anhydrous Na2SO4, filtered, and concentrated. The residue
was washed with n-hexane and dried to give target compound 25d.
2-(4-(Piperidine-1-carbonyl)benzamido)thiophene-3-carboxa-
mide (25d). White solid; yield 70%; mp 180−181 °C. 1H NMR (400
MHz, DMSO-d6) δ: 13.48 (brs, 1H), 8.08 (brs, 1H), 7.97 (d, J = 8.0Hz,
2H), 7.67 (brs, 1H), 7.60 (d, J = 8.0 Hz, 2H), 7.51 (d, J = 6.0 Hz, 1H),
7.07 (d, J = 6.0 Hz, 1H), 3.61 (brs, 2H), 3.25 (brs, 2H), 1.61−1.57 (m,
4H), 1.47 (brs, 2H). 13C NMR (100 MHz, DMSO-d6) δ: 167.9, 167.4,
162.0, 146.2, 140.6, 132.7, 127.5, 127.3, 123.3, 116.8, 115.9, 48.1, 42.4,
26.0, 25.3, 24.1. HRMS (ESI): m/z [M + H]+ calcd for C18H20N3O3S,
358.1220; found, 358.1222.
General Procedure for the Synthesis of Target Compounds 25e−
h.Target compounds 25e−hwere prepared from 4j (1.6 equiv) and the
corresponding aminothiophene intermediates 11a−d (1 equiv) in the
same manner as described for 23a−p.
Methyl 1-(2-(4-(Piperidine-1-carbonyl)benzamido)thiophene-3-
carbonyl)azetidine-3-carboxylate (25e). Yellow solid; yield 29%;
mp 154−155 °C. 1HNMR (500MHz, CDCl3) δ: 13.22 (brs, 1H), 8.12
(d, J = 7.5 Hz, 2H), 7.57 (d, J = 7.5 Hz, 2H), 7.08 (d, J = 5.5 Hz, 1H),
6.89 (d, J = 5.5 Hz, 1H), 4.75 (brs, 2H), 4.47 (brs, 2H), 3.84 (s, 3H),
3.78 (s, 2H), 3.63−3.60 (m, 1H), 3.35 (brs, 2H), 1.74−1.57 (m, 6H).
13C NMR (150 MHz, DMSO-d6) δ: 173.1, 168.2, 166.5, 162.4, 147.6,
141.0, 132.9, 127.9, 127.7, 123.3, 117.8, 114.3, 55.8, 52.6, 51.6, 48.4,
42.7, 32.6, 26.4, 25.7, 24.5. HRMS (ESI): m/z [M + H]+ calcd for
C23H26N3O5S, 456.1588; found, 456.1549.
Methyl 1-(2-(4-(Piperidine-1-carbonyl)benzamido)thiophene-3-
carbonyl)piperidine-4-carboxylate (25f). Grey solid; yield 19%; mp
169−170 °C. 1H NMR (400 MHz, DMSO-d6) δ: 11.54 (brs, 1H), 7.94
(d, J = 8.0 Hz, 2H), 7.57 (d, J = 8.0 Hz, 2H), 7.15 (d, J = 5.6 Hz, 1H),
7.04 (d, J = 5.6 Hz, 1H), 4.09 (brs, 2H), 3.61 (brs, 5H), 3.25 (brs, 2H),
3.10 (brs, 2H), 2.71−2.65 (m, 1H), 1.91−1.89 (m, 2H), 1.62−1.47 (m,
8H). 13C NMR (150 MHz, DMSO-d6) δ: 174.8, 168.3, 165.7, 163.1,
142.9, 140.7, 133.4, 128.1, 127.5, 124.7, 119.5, 118.1, 55.4, 52.0, 48.4,
42.7, 38.7, 28.3, 26.4, 25.7, 24.5. HRMS (ESI):m/z [M + H]+ calcd for
C25H30N3O5S, 484.1901; found, 484.1908.
Methyl 4-(2-(4-(Piperidine-1-carbonyl)benzamido)thiophene-3-
carbonyl)piperazine-1-carboxylate (25g). White solid; yield 17%;
mp 113−114 °C. 1H NMR (400 MHz, DMSO-d6) δ: 11.58 (s, 1H),
7.94 (d, J = 8.0 Hz, 2H), 7.58 (d, J = 8.0 Hz, 2H), 7.17 (d, J = 5.6 Hz,
1H), 7.07 (d, J = 5.6 Hz, 1H), 3.62 (s, 3H), 3.61−3.59 (m, 6H), 3.48−
3.45 (m, 4H), 3.24 (brs, 2H), 1.62−1.57 (m, 4H), 1.47 (brs, 2H). 13C
NMR (150 MHz, DMSO-d6) δ: 167.8, 165.6, 162.7, 155.0, 142.9,
140.3, 132.9, 127.6, 127.1, 124.2, 118.4, 117.6, 52.5, 47.9, 43.2, 42.2,
25.9, 25.2, 24.0. HRMS (ESI): m/z [M + H]+ calcd for C24H29N4O5S,
485.1853; found, 485.1859.
Ethyl 4-(2-(4-(Piperidine-1-carbonyl)benzamido)thiophene-3-
carbonyl)piperazine-1-carboxylate (25h). White solid; yield 21%;
mp 134−135 °C. 1H NMR (500 MHz, DMSO-d6) δ: 11.59 (brs, 1H),
7.94 (d, J = 7.0 Hz, 2H), 7.58 (d, J = 7.5 Hz, 2H), 7.17 (d, J = 5.0 Hz,
1H), 7.08 (d, J = 5.0 Hz, 1H), 4.06 (d, J = 7.0 Hz, 2H), 3.60 (brs, 6H),
3.47 (brs, 4H), 3.24 (brs, 2H), 1.62−1.46 (m, 6H), 1.19 (t, J = 6.5 Hz,
3H). 13C NMR (100 MHz, DMSO-d6) δ: 168.3, 166.0, 163.1, 155.1,
143.4, 140.8, 133.3, 128.1, 127.6, 124.7, 118.9, 118.1, 61.4, 48.4, 43.6,
42.7, 26.3, 25.7, 24.5, 15.0. HRMS (ESI): m/z [M + H]+ calcd for
C25H31N4O5S, 499.2010; found, 499.2003.
General Procedure for the Synthesis of Target Compounds 25i−
q. To a solution of compounds 22a−h (1 equiv) in anhydrous DMF
were added the corresponding benzoic acid 4j or 7f (1.2 equiv), EDCI
(1.3 equiv), HOBt (1.3 equiv), and Et3N (2.5 equiv) in turn. The
reaction mixture was stirred for 24 h under argon at room temperature,
then quenched with water, and extracted with EA thrice. The combined
organic phase was washed with brine, dried over anhydrous Na2SO4,
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filtered, and evaporated in vacuo. The residue was purified by silica gel
column chromatography (CH2Cl2/MeOH = 100/1) to give target
compounds 25i−q.
N-(5-Methylthiazol-2-yl)-2-(4-(piperidine-1-carbonyl)-
benzamido)thiophene-3-carboxamide (25i).White solid; yield 32%;
mp 236−238 °C. 1H NMR (400 MHz, DMSO-d6) δ: 12.74 (brs, 1H),
12.38 (brs, 1H), 8.00 (d, J = 6.8 Hz, 2H), 7.90 (s, 1H), 7.64 (d, J = 6.4
Hz, 2H), 7.26 (s, 1H), 7.15 (s, 1H), 3.62 (brs, 2H), 3.27 (brs, 2H), 2.39
(s, 3H), 1.62−1.48 (m, 6H). 13CNMR (150MHz, DMSO-d6) δ: 167.8,
163.7, 162.3, 162.2, 147.8, 140.6, 132.5, 129.6, 127.4, 127.3, 126.7,
123.2, 117.0, 115.1, 48.0, 42.3, 26.0, 25.2, 24.0, 11.2. HRMS (ESI):m/z
[M + H]+ calcd for C22H23N4O3S2, 455.1206; found, 455.1199.
N-(4-Methylpyrimidin-2-yl)-2-(4-(piperidine-1-carbonyl)-
benzamido)thiophene-3-carboxamide (25j). Yellow solid; yield 29%;
mp 177−178 °C. 1H NMR (500 MHz, DMSO-d6) δ: 13.01 (brs, 1H),
10.93 (brs, 1H), 8.66 (d, J = 4.5 Hz, 1H), 8.03 (d, J = 7.5 Hz, 2H), 7.88
(d, J = 5.5 Hz, 1H), 7.64 (d, J = 7.5 Hz, 2H), 7.24 (d, J = 4.5 Hz, 1H),
7.16 (d, J = 5.5 Hz, 1H), 3.64 (s, 2H), 3.28 (s, 2H), 2.52 (s, 3H), 1.64−
1.49 (m, 6H). 13C NMR (100 MHz, DMSO-d6) δ: 167.2, 166.6, 163.0,
161.1, 156.8, 156.1, 146.8, 139.4, 131.2, 126.2, 122.3, 116.1, 115.6,
114.6, 46.8, 41.1, 24.8, 24.1, 22.8, 22.3. HRMS (ESI): m/z [M + H]+
calcd for C23H24N5O3S, 450.1594; found, 450.1591.
2-(3-Fluoro-4-(piperidine-1-carbonyl)benzamido)-N-(4-methyl-
pyrimidin-2-yl)thiophene-3-carboxamide (25k). Yellow solid; yield
17%; mp 148−150 °C. 1H NMR (400 MHz, DMSO-d6) δ: 12.95 (brs,
1H), 10.91 (brs, 1H), 8.63 (d, J = 5.2 Hz, 1H), 7.85 (d, J = 5.6 Hz, 1H),
7.80 (t, J = 8.4 Hz, 2H), 7.66 (t, J = 7.6 Hz, 1H), 7.21 (d, J = 5.2 Hz,
1H), 7.15 (d, J = 6.0 Hz, 1H), 3.63 (brs, 2H), 3.19 (brs, 2H), 2.48 (s,
3H), 1.65−1.53 (m, 4H), 1.45 (brs, 2H). 13C NMR (100 MHz,
DMSO-d6) δ: 168.9, 164.5, 163.2, 161.7, 158.4, 158.0 (J = 246 Hz),
157.7, 156.8, 148.1, 135.3 (J = 7 Hz), 130.1, 129.0 (J = 19 Hz), 124.0,
117.7, 117.4, 116.6, 115.4 (J = 23 Hz), 47.9, 42.5, 26.4, 25.7, 24.3, 24.0.
HRMS (ESI): m/z [M + H]+ calcd for C23H23FN5O3S, 468.1500;
found, 468.1497.
2-(4-(Piperidine-1-carbonyl)benzamido)-N-(4-(trifluoromethyl)-
pyrimidin-2-yl)thiophene-3-carboxamide (25l). Yellow solid; yield
31%; mp 182−183 °C. 1H NMR (400 MHz, DMSO-d6) δ: 12.76 (brs,
1H), 11.40 (brs, 1H), 9.15 (d, J = 5.2 Hz, 1H), 7.99 (d, J = 8.4 Hz, 2H),
7.85 (d, J = 6.0 Hz, 1H), 7.79 (d, J = 5.2 Hz, 1H), 7.61 (d, J = 8.4 Hz,
2H), 7.15 (d, J = 5.6 Hz, 1H), 3.60 (brs, 2H), 3.24 (brs, 2H), 1.61−1.46
(m, 6H). 13C NMR (100 MHz, DMSO-d6) δ: 168.2, 164.6, 162.9,
162.7, 158.7, 155.3 (q, J = 35 Hz), 149.0, 141.1, 132.8, 127.9, 127.8,
124.1, 120.9 (q, J = 274 Hz), 117.3, 116.0, 113.5, 48.4, 42.7, 26.4, 25.7,
24.5. HRMS (ESI): m/z [M + H]+ calcd for C23H21F3N5O3S,
504.1312; found, 504.1306.
N-(5-Methylpyrazin-2-yl)-2-(4-(piperidine-1-carbonyl)-
benzamido)thiophene-3-carboxamide (25m). White solid; yield
47%; mp 177−179 °C. 1H NMR (500 MHz, CDCl3) δ: 12.82 (brs,
1H), 9.54 (brs, 1H), 8.21−8.18 (m, 2H), 8.10 (d, J = 7.5 Hz, 2H), 7.58
(d, J = 7.0 Hz, 2H), 7.21 (d, J = 5.0 Hz, 1H), 6.94 (d, J = 5.0 Hz, 1H),
3.75 (brs, 2H), 3.34 (brs, 2H), 2.58 (s, 3H), 1.71−1.55 (m, 6H). 13C
NMR (100 MHz, DMSO-d6) δ: 168.2, 164.9, 162.7, 149.5, 148.4,
146.4, 142.2, 141.1, 137.7, 132.9, 127.9, 127.8, 123.7, 117.5, 115.6, 48.4,
42.7, 26.4, 25.7, 24.5, 20.9. HRMS (ESI): m/z [M + H]+ calcd for
C23H24N5O3S, 450.1594; found, 450.1588.
N-(6-Methylpyridin-2-yl)-2-(4-(piperidine-1-carbonyl)-
benzamido)thiophene-3-carboxamide (25n).White solid; yield 46%;
mp 171−174 °C. 1H NMR (500 MHz, DMSO-d6) δ: 13.03 (brs, 1H),
10.63 (brs, 1H), 8.01−7.98 (m, 4H), 7.76 (t, J = 8.0 Hz, 1H), 7.62 (d, J
= 7.5 Hz, 2H), 7.13 (d, J = 5.5 Hz, 1H), 7.07 (d, J = 7.0 Hz, 1H), 3.61
(brs, 2H), 3.25 (brs, 2H), 2.47 (s, 3H), 1.62−1.47 (m, 6H). 13C NMR
(100 MHz, DMSO-d6) δ: 168.2, 165.0, 162.6, 157.2, 151.3, 148.0,
141.1, 138.8, 133.0, 127.9, 127.8, 123.8, 119.9, 117.2, 116.1, 113.3, 48.4,
42.7, 26.4, 25.7, 24.5, 24.0. HRMS (ESI): m/z [M + H]+ calcd for
C24H25N4O3S, 449.1642; found, 449.1641.
N-(4-Methylpyridin-2-yl)-2-(4-(piperidine-1-carbonyl)-
benzamido)thiophene-3-carboxamide (25o).White solid; yield 27%;
mp 148−149 °C. 1H NMR (400 MHz, DMSO-d6) δ: 12.96 (brs, 1H),
10.61 (brs, 1H), 8.28 (d, J = 5.2 Hz, 1H), 8.02 (s, 1H), 8.00 (s, 2H),
7.95 (d, J = 6.0 Hz, 1H), 7.63 (dd, J = 6.8, 1.6 Hz, 2H), 7.13 (d, J = 6.0
Hz, 1H), 7.06 (dd, J = 5.2, 0.8 Hz, 1H), 3.61 (brs, 2H), 3.26 (brs, 2H),
2.39 (s, 3H), 1.63−1.48 (m, 6H). 13C NMR (100 MHz, DMSO-d6) δ:
168.2, 164.9, 162.8, 152.0, 149.4, 148.1, 147.0, 141.1, 133.0, 127.9,
127.8, 123.8, 121.8, 117.3, 116.7, 116.1, 48.4, 42.8, 26.5, 25.7, 24.5,
21.4. HRMS (ESI): m/z [M + H]+ calcd for C24H25N4O3S, 449.1642;
found, 449.1641.
N-(4,6-Dimethylpyrimidin-2-yl)-2-(4-(piperidine-1-carbonyl)-
benzamido)thiophene-3-carboxamide (25p).White solid; yield 32%;
mp 189−190 °C. 1H NMR (400 MHz, DMSO-d6) δ: 12.94 (brs, 1H),
10.81 (brs, 1H), 7.99 (d, J = 8.0 Hz, 2H), 7.83 (d, J = 6.0 Hz, 1H), 7.61
(d, J = 8.0 Hz, 2H), 7.12 (d, J = 5.6 Hz, 1H), 7.09 (s, 1H), 3.60 (brs,
2H), 3.24 (brs, 2H), 2.43 (s, 6H), 1.61−1.46 (m, 6H). 13C NMR (100
MHz, DMSO-d6) δ: 168.3, 168.2, 164.6, 162.8, 157.5, 148.2, 141.1,
132.9, 127.9, 127.8, 123.9, 117.2, 117.0, 116.3, 48.4, 42.7, 26.4, 25.8,
24.5, 23.8. HRMS (ESI): m/z [M + H]+ calcd for C24H26N5O3S,
464.1751; found, 464.1751.
N-(5-Methylbenzo[d]thiazol-2-yl)-2-(4-(piperidine-1-carbonyl)-
benzamido)thiophene-3-carboxamide (25q).White solid; yield 56%.
mp > 250 °C. 1H NMR (500 MHz, DMSO-d6) δ: 12.71 (brs, 1H),
12.61 (brs, 1H), 8.02 (d, J = 7.0 Hz, 2H), 7.98 (s, 1H), 7.81 (s, 1H),
7.66 (d, J = 7.0Hz, 3H), 7.29 (d, J = 8.0Hz, 1H), 7.19 (s, 1H), 3.62 (brs,
2H), 3.27 (brs, 2H), 2.43 (s, 3H), 1.63−1.49 (m, 6H). 13C NMR (100
MHz, DMSO-d6) δ: 167.7, 163.7, 162.5, 157.1, 148.8, 146.5, 140.7,
133.3, 132.4, 131.9, 127.6, 127.4, 123.0, 121.3, 120.0, 117.4, 114.3, 48.0,
42.3, 25.9, 25.2, 24.0, 21.0. HRMS (ESI): m/z [M + H]+ calcd for
C26H25N4O3S2, 505.1363; found, 505.1360.
Biological Evaluation. MIC Determination. MICs against
replicating M. tuberculosis H37Rv or clinical isolates were determined
by the microplate Alamar blue assay (MABA) following the protocol as
described previously.24,25 RFP, INH, and TCA1 were included as
positive controls. M. tuberculosis H37Rv or isolated clinical strains were
grown to the late log phase (70−100 Klett units) in Difco Middlebrook
7H9 Broth (Seebio) supplemented with 0.2% (v/v) glycerol, 0.05%
Tween 80, and 10% (v/v) albumin−dextrose−catalase (Seebio) (7H9-
ADC-TG). Cultures were centrifuged, washed twice, and then
resuspended in phosphate-buffered saline. Suspensions were then
passed through an 8 μm pore size filter to remove clumps, and aliquots
were frozen at−80 °C. Twofold dilutions of compounds were prepared
in 7H9-ADC-TG in a volume of 100 μL in 96-well clear-bottom
microplates (BD). M. tuberculosis (100 μL containing 2 × 105 CFU)
was added to yield a final testing volume of 200 μL. The plates were
incubated at 37 °C; on day 7 of incubation, 12.5 μL of 20% Tween 80
and 20 μL of Alamar blue were added to all wells. After incubation at 37
°C for 16−24 h, the fluorescence was read at an excitation of 530 nm
and an emission of 590 nm. The MIC was defined as the lowest
concentration resulting in a reduction in fluorescence of ≥90% relative
to the mean of replicate bacterium-only controls.
Cytotoxicity Assay.24,25 Vero cells and HepG2 cells were cultured in
Roswell Park Memorial Institute (RPMI) 1640 medium supplemented
with 10% fetal bovine serum (FBS). The cells were incubated in a
humidified atmosphere of 5% CO2 at 37 °C. Stocks of cells were
cultured in 25 cm2 tissue culture flasks and subcultured two to three
times per week. Cytotoxicity testing was performed in a transparent 96-
well microplate. Outer perimeter wells were filled with sterile water to
prevent dehydration in experimental wells. The cells were incubated at
37 °C under 5% CO2 until confluency and then diluted with the culture
medium to 4 × 105 cells/mL. Threefold serial dilutions of the stock
solutions resulted in final concentrations of 64 to 0.26 μg/mL in a final
volume of 100 μL. After incubation at 37 °C for 48 h, the medium was
removed and the monolayers were washed twice with 100 μL of warm
Hanks balanced salt solution (HBSS). Warm medium (100 μL) and 10
μL of freshly made methyl-thiazolyldiphenyl-tetrazolium bromide
(MTT) were added to each well, and then, the plates were incubated
for 4 h, after which the absorbance was determined at 492 nm.
Antituberculosis Activity in Macrophages. The assays were
performed as described previously using mouse J774A.1 macro-
phages.26 The final concentrations of selected compounds were 10
μg/mL and 5 μg/mL. The concentration of rifampicin (RFP) as the
positive control was 5 μg/mL. All assays were performed in triplicate in
at least three separate experiments.
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DprE1 Inhibition Assay. DprE1 assays were performed as described
previously.27 Briefly, assays were performed at 30 °C in 384-well black
plates in buffer containing 50 mM N-(2-hydroxyethyl)piperazine-N′-
ethanesulfonic acid (Hepes), pH 7.5, 100 mM NaCl, 1.5% (v/v)
DMSO, 100 μM Tween-20, 2 μM FAD, and 50 μM resazurin, with
variable concentrations of FPR and DprE1. Reactions were monitored
by following an increase in fluorescence intensity (λex = 530 nm, λem =
595 nm) associated with the formation of resorufin. For inhibition
studies, DprE1 (1 μM) was measured by the resazurin assay with 1 mM
FPR in the presence of different inhibitor concentrations. The IC50
values were obtained by plotting the initial velocities with inhibitor
concentrations. The IC50 values were calculated using the software
program GraphPad Prism.
MIC Assay against the Strain Overexpressing DprE1.27 Mt-DprE1
was cloned into the plasmid pMV261 to generate pMV261-Mt-dprE1
and introduced into M. bovis BCG Pasteur. This host−plasmid system
permits the constitutive expression of target proteins. After the bacteria
were incubated in the presence of the compound for 7 days, cell viability
can be assessed by the ability of endogenous reductases to reduce
resazurin to resorufin. As a proof of concept, cells transformed with
pMV261-Mt-dprE1 grew in the presence of TCA1 with aMIC >16-fold
higher than that when cells were transformed with an empty vector.
Cells transformed with pMV261-Mt-dprE1 did not confer any growth
advantage over cells transformed with the vector alone when cells were
grown in the presence of INH.
Hepatocyte Stability Assay. The assay was performed with
hepatocytes from male mice (BioIVT) and mixed humans (BioIVT)
following the protocol described previously.25 The assay evaluated the
metabolic stability of compounds in hepatocytes by measuring the
amount of parent compounds remaining of the test samples.
Inhibition Evaluation on the hERG K+ Channel. Electrophysiology
recording of the hERG channel current was carried out following the
standard protocol as described previously.28 hERG current inhibition in
the presence of five concentrations, including 30, 10, 3.0, 1.0, and 0.3
μM, was tested for IC50 determination. Dofetilide was also included as a
positive control to ensure the accuracy and sensitivity of the test system.
All experiments were performed in duplicate for IC50 determination.
The compound with IC50 > 30 μM was generally considered to have a
lower potential for hERG K+ channel inhibition.
Pharmacokinetic Studies in Mice.29 All animal protocols were
approved by the Institute Animal Care and Welfare Committee of
Shanghai Bioduro Biologics Co., Ltd. The selected compounds 25a,
24f, and TCA1 were subjected to pharmacokinetic studies in Balb/c
mice (male) weighing 26−27 g with three mice in the oral
administration group and three mice in the intravenous injection
group. The tested compound was formulated at a concentration of 5
mg/mL for a dose of 50 mg/kg given orally (p.o.) and at 1 mg/mL for a
dose of 5 mg/kg given intravenously (i.v.). The tested compound was
formulated with 0.5% carboxymethyl cellulose for p.o. administration
and with a mix solution (10%DMSO/50%poly(ethylene glycol)
(PEG)400/40%water) for i.v. administration. Blood samples were
collected at 5, 15, 30 min, 1, 2, 4, 7, 24 h after oral dosing and i.v.
administration. Plasma was harvested and stored at −80 °C until
analyzed. The pharmacokinetic parameters were calculated using
WinNonlin software version 6.3 based on noncompartmental analysis
(Pharsight Corporation, Mountain View). The oral bioavailability was
calculated as the ratio between the area under the curve (AUC)
following intravenous administration corrected for dose (F = (AUCp.o.
× dosei.v.)/(AUCi.v. × dosep.o.)).
In Vivo TB Infection Assay.30 All animal protocols were approved by
the Institute Animal Care and Welfare Committee of Beijing
Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest
Hospital, Capital Medical University. SPF Balb/c mice (female, 18−20
g) were used in this study. Each treated group was composed of six
mice. Mice were infected via aerosol with a suspension of 5× 106 CFU/
mLM. tuberculosisH37Rv using a Glas-Col inhalation system to deposit
50−100 bacilli into the lungs of each animal. The course of infection
was followed by plating homogenates of harvested organs [n = 3] on
7H11 agar plates (7H11 plates containing 10% oleic acid−albumin−
dextrose−catalase (OADC) enrichment and 50 μg/mL cycloheximide,
200 U/mL polymyxin B, 50 μg/mL carbenicillin, and 20 μg/mL
trimethoprim) and determining CFUs on days 3, 10, and 30
postinfection. INH, TCA1, and 25a were dissolved or suspended in
0.5% CMC and administered by oral gavage in a maximum volume of
200 μL such that doses of 25 and 100 mg/kg body weight were
achieved. The control group received only 0.5% CMC. Mice were
treated 5/7 days per week during the acute phase of infection, from day
10 to 30.Mice were sacrificed the day after the last day of treatment, and
lungs were removed, homogenized, and serially diluted in 10-fold steps
in HBSS. A total of 100 μL was spread on 7H11 agar in duplicate. The
plates were incubated at 37 °C for 3 weeks. Data are expressed as log10
(and as log10 reduction) provided by the given dose of the compound
against the growth of the organism in the untreated control group.
Mean log10 values were calculated from bacterial burden counts.
Student’s t test was used to compare means between the test and
control groups. A P value of ≤0.05 was considered significant.
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WT, wild type; XDR-TB, extensively drug-resistant tuberculosis
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